ПРОТИВОМИКРОБНЫЕ СВЕРХВПИТЫВАЮЩИЕ КОМПОЗИЦИИ

FIBRINOGENKONZENTRATE AUS BLUTPLASMA, VERFAHREN UND ANLAGE FÜR IHRE HERSTELLUNG

Lokal applizierbares Arzneimittel mit verzögerter Freisetzung

FIBRINMIKROKUGELN AND THEIR USES

ENRICHED PLASMA DERIVATIVE FOR THE SUPPORT OF WUNDVERSCHLUSS AND WUNDABDECKUNG.

ENRICHED PLASMA DERIVATIVE FOR THE SUPPORT OF WUNDVERSCHLUSS AND CICATRISATION.

FIBRIN OR FIBRINOGEN AS WELL AS BIOLOGICAL DEGRADABLE ONE AND BIOCOMPATIBLE OF POLYMERS CONTAINING COMPOSITION FOR FABRIC TREATMENT

Hemostatic products

A hemostatic product that includes a fibrinogen mixture, a thrombin mixture and a biologically tolerable liquid. The fibrinogen mixture includes fibrinogen and at least one fibrinogen stabilizer. The thrombin mixture includes thrombin and at least one thrombin stabilizer. The biologically tolerable liquid is mixed with the fibrinogen mixture and the thrombin mixture to form the hemostatic product.

Stable pharmaceutical foam

Provided are pharmaceutical foam compositions comprising a peptone, a peptide hydrolysate or an enzymatically-hydrolyzed protein prepared by enzymatic hydrolysis of a full-length protein; methods of preparation and uses thereof.

Process of making flowable hemostatic compositions and devices containing such compositions

SEALANT FORMULATION AND USES THEREOF

The present invention relates to a sealant formulation comprising a blend containing fibrinogen and an exogenous activator of a member of a mammalian blood clotting cascade.

TISSUE TREATMENT COMPOSITION COMPRISING FIBRIN OR FIBRINOGENAND BIODEGRADABLE AND BIOCOMPATIBLE POLYMER

... 2111193 9222312 PCTABS00018 A tissue treatment composition, especially an adhesive composition comprises (i) fibrin or fibrinogen and (ii) a biodegradable and biocompatible polymer capable of forming a viscous aqueous solution. In addition to glueing, the tissue adhesive composition may be used for slow-release of a drug incorporated into it or for anti-adherence purposes, for wound healing, etc.

CONCENTRATE OF FIBRINOGENE OBTAINED FROM BLOOD PLASMA, PROCESS AND PLANT FOR ITS PREPARATION

The present invention relates to a fibrinogen concentrate which is characterized in that it is free of viral contaminents and in that its purit y is higher than 95%. The present invention also relates to the process for obtaining such fibrinogen concentrate.

CONCENTRATE OF FIBRINOGENE OBTAINED FROM BLOOD PLASMA, PROCESS AND PLANT FOR ITS PREPARATION

The present invention relates to a fibrinogen concentrate which is characterized in that it is free of viral contaminants and in that its purity is higher than 95 %. The present invention also relates to the process for obtaining such fibrinogen concentrate.

SUPPLEMENTED AND UNSUPPLEMENTED TISSUE SEALANTS, METHODS OF THEIR PRODUCTION AND USE

This invention provides a fibrin sealant bandage or dressing, wherein said fibrin sealant may be supplemented with at least one composition selected from, for example, one or more regulatory compounds, antibody, antimicrobial compositions, analgesics, anticoagulants, antiproliferatives, antiinflammatory compounds, cytokines, cytotoxins, drugs, growth factors, interferons, hormones, lipids, demineralized bone or bone morphogenetic proteins, cartilage inducing factors, oligonucleotides, polymers, polysaccharides, polypeptides, protease inhibitors, vasoconstrictors or vasodilators, vitamins, minerals, stabilizers and the like. Also disclosed are methods of preparing and/or using the unsupplemented or supplemented fibrin sealant bandage or dressing.

Depot formulations

The depot formulation containing fibronectin or a fragment thereof, a growth factor binder bound thereto, and a growth factor bound to the binder, is used for increasing the rate of wound healing.

МНОГОСЛОЙНЫЙ ПРОДУКТ КРОВИ

Продукт крови (10), способ получения продукта крови, продукт крови, получаемый способом, и контейнерное средство получения продукта крови. Продукт крови содержит компоненты из цельной крови, особенно фибрин, тромбоциты и лейкоциты. Продукт крови (10) содержит первый слой (21), второй слой (22) и третий слой (23). Второй слой (22) смежный с первым слоем (21) и третьим слоем (23). Первый слой (21) определяет первую внешнюю поверхность (24) продукта крови (10), а третий слой (23) определяет вторую внешнюю поверхность (25) продукта крови (10). Первый слой (21) содержит большую часть фибрина, второй слой (22) содержит большую часть тромбоцитов, а третий слой (23) содержит большую часть лейкоцитов.

DEVICE FOR PREPARING A BIOLOGICAL WOUND DRESSING MADE OF AUTOLOGOUS FIBRIN

A device for preparing a biological wound dressing made of autologous fibrin. The device includes a cylindrical container with a bottom which is inclined from the side slopes towards a central channel with a slope that leads the liquid sealant remaining from pressing the fibrin clot through the sieve towards the outlet and from there to the multiduct collection system.

Enriched plasma derivative for promoting wound sealing and wound healing

Enriched plasma deriv. (A) comprises components exclusively in powdered form and its compsn. is chosen with regard (a) to optimal activation of exogenous and/or endogenous blood coagulation systems and (b) to a number of physiological and opt. pathological considerations. The major components are fibrinogen (I), thrombin (II), components of the prothrombin (III) complex and protease inhibitors. It may also contain thrombocyte extracts, antibiotics, etc. A pref. formulation contains 60-96 wt.% (I), practically free of water-insoluble globulins (content pref. below 2 wt.%); 0.05-5 wt.% fibrinolysis inhibitors; 0.1-15 wt.% (II) and/or (III). All components are in solid, powdered forms and are simply mixed together. (A) is a biochemical substrate for accelerating haemostasis and optimal regulation of wound closure. It has an almost unlimited storage life at room temp. without agglomeration; can be used directly without any additives, and is quickly soluble in body fluids.

PRODUCTS COMPRISING FIBRINOGEN FOR USE IN THERAPY

A product comprises thrombin and microparticles having bound fibrinogen, as a combined preparation for simultaneous use in wound therapy or surgical repair. Another aspect lies in the use of insoluble microparticles having fibrinogen bound thereto, for the manufacture of a medicament for use in wound therapy or surgical repair of a patient having an abnormally low level of platelets.

SUPPLEMENTIERTE VERDICHTUNGSMITTEL FÜR GEWEBE, METHODEN FÜR IHRE HERSTELLUNG UND IHRE VERWENDUNG

FLEXIBLE WUNDAUFLAGE ON FIBRINBASIS AND PROCEDURES FOR YOUR PRODUCTION

FIBRINSCHWAMM

FIBRINSCHWAMM

PROCEDURE FOR THE PRODUCTION CELEBRATIONS OF A FEDERATION FOR THE TREATMENT OF INJURED FABRIC

Fibrin-cell suspension for construction of new tissue

Process of making flowable hemostatic compositions and devices containing such compositions

The present invention provides a method of making flowable hemostatic compositions and medical devices containing such compositions. 'A' p-f N ...

Fibrin foam and process

A fibrin wound dressing is made by mixing quantities of fibrinogen solution and thrombin solution with air. The resulting foam is very light weight, and with the proper attention to the amount of thrombin, is also sufficiently viscous to rest on a vertical surface without dripping. The wound dressing may also be formulated for its ability to continue migration of healing substances, such as PDGF, from the dressing to the wound site. Thrombin substitutes, such as other clotting proteins, may be used instead of thrombin. The resulting foam may also be lyophilized or ground and lyophilized for later reconstitution. A therapeutic drug or other additive may also be added to the wound dressing.

Wound-treating absorbent

The present disclosure provides wound-treating absorbent kits that comprise a set of hemostatic compositions including at least (1) a first hemostatic composition including a first crosslinked polysaccharide selected from the group consisting of cyclodextrin and dextran, and (2) a second hemostatic composition including a second crosslinked polysaccharide selected from the group consisting of cyclodextrin and dextran. In some embodiments, the first hemostatic composition has a first degree of crosslinking, and the second hemostatic composition has a second degree of crosslinking higher than the first degree of crosslinking. Also provided are methods of treating a wound by selecting a hemostatic composition from the disclosed set of hemostatic compositions, and administering the selected hemostatic composition to a site of the wound.

HEMOSTATIC COMPOSITIONS CONTAINING STERILE THROMBIN

... ²²²The present invention includes sterilized hemostatic compositions that contain ²a continuous, biocompatible liquid phase having a solid phase of particles of ²a biocompatible polymer suitable for use in hemostasis and that is ²substantially insoluble in the liquid phase, and sterile thrombin, each of ²which is substantially homogenously dispersed throughout the continuous liquid ²phase, and methods for making such compositions.² ...

PROCESS OF MAKING FLOWABLE HEMOSTATIC COMPOSITIONS AND DEVICES CONTAINING SUCH COMPOSITIONS

... ²²²The present invention is directed to processes of making flowable hemostatic ²compositions and devices that include the flowable hemostatic composition ²disposed therein, where a volume of biocompatible liquid, a volume of a ²biocompatible gas, and an amount of solid particles of a biocompatible polymer ²are mixed together to form a substantially homogenous composition including a ²discontinuous gas phase and the solid particles substantially homogenously ²dispersed throughout a continuous liquid phase to form a flowable hemostatic ²composition, and the composition then transferred into a device suitable for ²applying the flowable hemostatic composition to a site of a body requiring ²hemostasis under conditions effective to maintain the substantially homogenous ²dispersion of the gas phase and the solid particles throughout the liquid ²phase.² ...

FLEXIBLE WOUND COVERING BASED ON FIBRIN AND PROCESS FOR ITS PRODUCTION

A biodegradable, flexible wound covering based on fibrin and a process for its preparation are described, in which a fibrinogen solution is subjected t o a single-stage or multistage dialysis, then a flexible fibrin web is formed by action of an aqueous thrombin solution on the fibrinogen solution and this is subsequently subjected to freeze-drying.

FIBRIN SPONGE

The invention relates to a fibrin sponge comprising a residual moisture content of at least 3 %, preferably of 3 to 35 %, in particular 10 to 20 %, and preferably containing a blood clotting activator or proactivator, a method of preparing this fibrin sponge as well as a kit for wound gluing which comprises the fibrin sponge and a component containing a blood clotting factor. The sponge according to the present invention is suitable for hemostasis, tissue adhesion and aiding wound healing.

Apparatus for production of fibrin ogen or fibrin glue

This invention relates generally to apparatuses and processes for preparing fibrinogen glue from autologous plasma. More particularly, this invention relates to a novel apparatus comprising a plasma membrane separator to extract and separate the autologous plasma from other undesirable compositions in the blood. The autologous plasma is transferred to a membrane separator to provide separation of the fibrinogen from other compositions with a desirable amount of ether or other suitable solvents containing an-OH group in the presence of a mixing means. The fibrinogen so separated is transferred to a fibrinogen collector which is connected to a vacuum pump through a sterile filter to remove the ether or other suitable solvents contained thereof. A freezer is provided to maintain the autologous plasma in the membrane separator and the fibrinogen in the fibrinogen collector at a desirable temperature. Additionally, a constant temperature bisyringe serves to keep the fibrinogen liquid and mixed ...

Methods and Dressings for Sealing Internal Injuries

Disclosed are solid and frozen haemostatic materials and dressings consisting essentially of a fibrinogen component and a fibrinogen activator. Also disclosed are methods of treating internal wounded tissue in a mammal by applying one or more of these haemostatic materials and dressings.

Supplemented and unsupplemented tissue sealants, methods of their production and use

This invention provides a fibrin sealant dressing, wherein said fibrin sealant may be supplemented with at least one composition selected from, for example, one or more regulatory compounds, antibody, antimicrobial compositions, analgesics, anticoagulants, antiproliferatives, anti-inflammatory compounds, cytokines, cytotoxins, drugs, growth factors, interferons, hormones, lipids, demineralized bone or bone morphogenetic proteins, cartilage inducing factors, oligonucleotides polymers, polysaccharides, polypeptides, protease inhibitors, vasoconstrictors or vasodilators, vitamins, minerals, stabilizers and the like. Also disclosed are methods of preparing and/or using the unsupplemented or supplemented fibrin sealant dressing.

MULTIPURPOSE MEMBRANES, METHODS FOR FORMING, AND APPLICATIONS THEREOF

One aspect of the present disclosure relates to a method for forming a multipurpose membrane in vivo. One step of the method includes obtaining a blood component. Next, a vacuum assembly is operated to remove substantially all of the liquid from the blood component and thereby form a concentrated, substantially dehydrated blood component. The substantially dehydrated blood component is then formed into a non-coagulated injectable composition and administered to a wound of a subject.

FORMULATIONS FOR WOUND THERAPY

ФОРМОВАННЫЙ ПЛАСТИНЧАТЫЙ ПРОДУКТ И ГЕМОСТАТИЧЕСКИЙ МАТЕРИАЛ

FIELD: medicine.SUBSTANCE: group of inventions relates to medicine. Disclosed is a sheet moulding of a polymer composition, comprising at least one protein selected from the group consisting of fibrinogen and thrombin, and at least one polymer selected from the group consisting of an aliphatic polyester and a water-soluble polymer; and a laminated moulded laminate product comprising a first layer of a polymer composition consisting of fibrinogen and a water-soluble polymer, and a second layer of a polymer composition, consisting of thrombin and aliphatic polyester. Said moulded products are applied to a wound site and function as a haemostatic material.EFFECT: product has good supporting characteristics and solubility for haemostatic proteins and excellent flexibility.19 cl, 1 dwg, 3 tbl, 31 ex РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (13) 2 669 569 C2 (51) МПК A61L 24/10 (2006.01) A61L 15/44 (2006.01) A61K 38/00 (2006.01) A61K 38/48 (2006.01) A61K 47/34 (2006.01) A61P 7/04 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ОПИСАНИЕ ИЗОБРЕТЕНИЯ К ПАТЕНТУ (52) СПК A61L 24/10 (2006.01); A61L 15/44 (2006.01); A61K 38/00 (2006.01); A61K 38/48 (2006.01); A61K 47/34 (2006.01); A61P 7/04 (2006.01) (21)(22) Заявка: 2014150544, 13.05.2013 13.05.2013 Дата регистрации: 12.10.2018 14.05.2012 JP 2012-110392; 14.05.2012 JP 2012-110393; 14.05.2012 JP 2012-110394; 14.05.2012 JP 2012-110391; 11.01.2013 JP 2013-003273 (43) Дата публикации заявки: 10.07.2016 Бюл. № C 2 R U (86) Заявка PCT: (56) Список документов, цитированных в отчете о поиске: WO 2011/037760 A2, 31.03.2011. JP 2010-69031 A, 02.04.2010. WO 2006/028244 A1, 16.03.2006. (85) Дата начала рассмотрения заявки PCT на национальной фазе: 15.12.2014 JP 2013/063872 (13.05.2013) (87) Публикация заявки PCT: WO 2013/172472 (21.11.2013) Адрес для переписки: 109012, Москва, ул. Ильинка, 5/2, ООО "Союзпатент" (54) ФОРМОВАННЫЙ ПЛАСТИНЧАТЫЙ ПРОДУКТ И ГЕМОСТАТИЧЕСКИЙ МАТЕРИАЛ (57) Реферат: Группа изобретений относится к ...

ТВЕРДАЯ ПОВЯЗКА ДЛЯ ЛЕЧЕНИЯ ТРАВМИРОВАННОЙ ТКАНИ

Группа изобретений относится к медицине и может быть использована при лечении травмированных тканей. Предложены твердая повязка, способ ее использования и композиция для изготовления твердой повязки. Твердая повязка включает один гемостатический слой, полученный из одного водного раствора и состоящий из фибриногенового компонента и активатора фибриногена. При этом фибриногеновый компонент содержится в количестве, составляющем от 1,5 мг/см 2 до 13,0 мг/см 2 поверхности указанной повязки, обращенной к ране. Активатор фибриногена содержится в количестве от 2,50 единиц/мг указанного фибриногенового компонента до 0,025 единиц/мг указанного фибриногенового компонента. Повязку накладывают на травмированную ткань и прилагают достаточное давление в течение определенного периода времени, достаточного для образования фибрина в количестве, достаточном для снижения потери крови и/или другой физиологической жидкости из указанной травмированной ткани. Группа изобретений направлена на обеспечение удобства использования повязки за счет содержания в ее составе одновременно фибриногенового компонента и активатора фибриногена в одном слое. 4 н. и 37 з.п. ф-лы, 11 табл., 5 ил., 14 пр. РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) 2 480 191 (13) C2 (51) МПК A61F 13/00 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ОПИСАНИЕ ИЗОБРЕТЕНИЯ К ПАТЕНТУ (21)(22) Заявка: 2009107724/14, 06.08.2007 (24) Дата начала отсчета срока действия патента: 06.08.2007 (72) Автор(ы): МАКФИ Мартин (US), БИЛЛ Доусон (US) (43) Дата публикации заявки: 10.09.2010 Бюл. № 25 C 2 2 4 8 0 1 9 1 R U C 2 (56) Список документов, цитированных в отчете о поиске: US 6762336 В1, 13.07.2004. RU 2235539 С1, 10.09.2004. RU 2193897 С2, 27.08.2000. RU 98119893 F, 27.08.2000. US 4442655 А, 17.04.1984. US 6056970 А, 02.05.2000. МИЛАНОВ Н.О. и др. Использование фибринового клея для укрытия микрохирургических аутотрансплаптатов свободной расщепленной кожей, Хирургия, журнал им. Н.И.Пирогова, №12, 2004, Найдено (см. прод.) (85) ...

ТВЕРДАЯ ПОВЯЗКА ДЛЯ ЛЕЧЕНИЯ ТРАВМИРОВАННОЙ ТКАНИ

... 1. Твердая повязка для лечения травмированной ткани млекопитающего, где указанная повязка включает по меньшей мере один гемостатический слой, по существу, состоящий из фибриногенового компонента и активатора фибриногена, где указанный гемостатический слой получен из одного водного раствора, содержащего фибриногеновый компонент и активатор фибриногена. ! 2. Твердая повязка для лечения травмированной ткани млекопитающего, где указанная повязка включает по меньшей мере один гемостатический слой, по существу, состоящий из фибриногенового компонента и активатора фибриногена, где указанный гемостатический слой изготовлен путем литья в виде единого изделия. ! 3. Твердая повязка по п.1 или 2, также содержащая по меньшей мере один слой-носитель. ! 4. Твердая повязка по п.3, где слой-носитель содержит материал-основу. ! 5. Твердая повязка по п.3, где слой-носитель содержит внутренний материал-носитель. ! 6. Твердая повязка по п.3, где слой-носитель содержит ресорбируемый материал. ! 7. Твердая повязка ...

GEWEBEABDECKUNG UND WACHSTUMSFAKTOR ENTHALTENDE VERBINDUNGEN ZUR FÖRDERUNG BESCHLEUNIGTER WUNDHEILUNG

Composite material

FABRIC COVER AND GROWTH FACTOR CONTAINING CONNECTIONS TO THE PROMOTION OF ACCELERATED CICATRISATION

TEICOPLANINENTHALTENDES, RESTAURANT APPLIZIERBARES DRUG WITH RETARDED ACTIVE SUBSTANCE RELEASE

SUPPLEMENTIERTE COMPRESSION MEANS FOR FABRIC, METHODS FOR YOUR PRODUCTION AND YOUR USE

COMPOSITION TO THE PRODUCTION, REGENERATION AND REPAIR OF FABRICS USING A CELL-BASIC BIOLOGICAL IMPLANT, WHICH IS ENRICHED WITH A BLOOD PANEL CONCENTRATE AND SUPPLEMENTEN

Methods of making concentrated fibrinogen containing compositions and associated systems for preparing fibrin glue

Fibrin sponge

Hemostatic compositions containing sterile thrombin

ANTIMICROBIAL SUPERABSORBENT COMPOSITIONS

A composition has an enzyme that is able to convert a substrate to release hydrogen peroxide; a substrate for the enzyme; and a superabsorbent component, such as a superabsorbent polymer. The composition is in the form of a powder and may form a gel on contact with water.

COMPOSITIONS COMPRISING HEMOSTATIC COMPOUNDS AND BIOABSORBABLE POLYMERS

Solid, fibrous bioabsorbable hemostatic compositions containing a bioabsorbable polymer and a hemostatic compound, methods for making the hemostatic compositions, and methods for using the hemostatic compositions are disclosed.

SUPPLEMENTED AND UNSUPPLEMENTED TISSUE SEALANTS, METHODS OF THEIR PRODUCTION AND USE

This invention provides supplemented and unsupplemented tissue sealants (TSs), such as fibrin glue, as well as methods of their production and use. In one embodiment, this invention provides TSs that do not inhibit full thickness skin wound healing. This invention also provides growth factor(s)- and/or drug(s)- supplemented TSs and methods of their production and use. The particular drug(s) or growth factor(s) selected is a function of its use. In one embodiment, the TS is supplemented with a growth factor(s) and can be used to promote: wound healing, such as that of skin or bone; endothelialization of vascular protheses; the proliferation and/or differentiation of animal cells; and/or the directed migration of animal cells. Exemplified embodiments include fibrin glue that is supplemented with: fibroblast growth factor-1, -2 or -4; and/or bone morphogenetic proteins; and polytetrafluorethylene vascular grafts pressure perfused with fibrin glue containing HBGF-1. In another embodiment the supplemented TS is used to produce a localized delivery of a growth factor(s) and/or a drug(s). Exemplified include fibrin glue supplemented with solid 5-fluorouracil or free base tetracycline. In another embodiment, this invention provides TS supplemented or treated with a substance, such as free base tetracycline or ciprofloxacin HCl, wherein the longevity of the fibrin glue is increased.

HEMOSTATIC SANDWICH BANDAGE

The present invention relates to a haemostatic multilayer bandage that comprises preferably a thrombin layer between two fibrinogen layers. The dressing may contain other resorbable materials such as glycolic acid or lactic acid based polymers or copolymers. The inventive haemostatic sandwich bandage is useful for the treatment of wounded tissue.

HEMOSTATIC SANDWICH BANDAGE

The present invention relates to a haemostatic multilayer bandage that comprises preferably a thrombin layer between two fibrinogen layers. The dressing may contain other resorbable materials such as glycolic acid or lactic acid based polymers or copolymers. The inventive haemostatic sandwich bandage is useful for the treatment of wounded tissue.

FIBRIN FOAM AND PROCESS

A fibrin wound dressing is made by mixing quantities of fibrinogen solution and thrombin solution with air. The resulting foam is very light weight, and with the proper attention to the amount of thrombin, is also sufficiently viscous to rest on a vertical surface without dripping. The wound dressing may also be formulated for its ability to continue migration of healing substances, such as PDGF, from the dressing to the wound site. Thrombin substitutes, such as other clotting proteins, may be used instead of thrombin. The resulting foam may also be lyophilized or ground and lyophilized for later reconstitution. A therapeutic drug or other additive may also be added to the wound dressing.

PROCESS AND DEVICE FOR THE PREPARATION OF PLATELET RICH PLASMA FOR EXTEMPORANEOUS USE AND COMBINATION THEREOF WITH SKIN AND BONE CELLS

The present invention is relates to a new platelet-rich plasma preparation, a method of preparation thereof, a use thereof, a device for the preparation thereof and preparations containing such a platelet-rich plasma preparation. Specifically, the invention provides platelet-rich plasma preparations for use in tissue regeneration and bone regeneration.

Multipurpose membranes, methods for forming, and applications thereof

One aspect of the present disclosure relates to a method for forming a multipurpose membrane in vivo. One step of the method includes obtaining a blood component. Next, a vacuum assembly is operated to remove substantially all of the liquid from the blood component and thereby form a concentrated, substantially dehydrated blood component. The substantially dehydrated blood component is then formed into a non-coagulated injectable composition and administered to a wound of a subject.

Interpenetrating polymer network

The present invention relates to a material as interpenetrating polymer network (IPN) associating a gel with a co-network of functionalized synthetic polymer and functionalized protein as well as a method of the manufacture of such a material. In particular, the invention relates to a material as interpenetrating polymer network associating a fibrin gel with a co-network of polyvinylalcohol and albumin thank to methacrylate bridges, with improved biodegradability properties.

SOLID DRESSING FOR TREATING WOUNDED TISSUE

Disclosed are solid dressings for treated wounded tissue in mammalian patients, such as a human, comprising a haemostatic layer consisting essentially of a fibrinogen component and thrombin, wherein the thrombin is present in an amount between 0.250 Units/mg of fibrinogen component and 0.062 Units/mg of fibrinogen component. Also disclosed are methods for treating wounded tissue.

FIBRINOGEN COMPOSITION, METHOD AND WOUND ARTICLES

Disclosed is a fibrinogen composition. The fibrinogen composition comprises denatured fibrinogen hydrogel having a fibrinogen concentration ranging from 0.1 to 15 wt.-% and a fibrinogen hydrogel forming salt at a concentration less than a threshold concentration to form the fibrinogen hydrogel. In some examples, the fibrinogen composition is dehydrated denatured fibrinogen hydrogel, where the fibrinogen composition comprises salt at a concentration no greater than 20 wt.-%. 1. A fibrinogen composition comprisingdenatured fibrinogen hydrogel having a fibrinogen concentration ranging from 0.1 to 15 wt.-%;fibrinogen hydrogel forming salt at a concentration less than a threshold concentration to form the fibrinogen hydrogel.2. The fibrinogen composition of claim 1 , wherein the fibrinogen composition comprises at least 50 wt.-% water.3. The fibrinogen composition of claim 1 , wherein the fibrinogen hydrogel forming salt concentration is less than 0.45 wt-% of the fibrinogen composition.4. The fibrinogen composition of claim 1 , wherein the fibrinogen hydrogel forming salt comprises sodium citrate optionally in combination with sodium chloride.5. The fibrinogen composition of claim 1 , further comprising a plasticizer.6. The fibrinogen composition of wherein the plasticizer comprises a sugar alcohol claim 5 , an alkane diol claim 5 , or a combination thereof.7. The fibrinogen composition of claim 1 , further comprising a carrier material in an amount ranging from 0.1 to about 50 wt.-%.8. The fibrinogen composition of wherein the carrier material comprises a water-soluble polymer.9. The fibrinogen composition of claim 8 , wherein the water-soluble polymer comprises polymerized units of N-vinyl lactam polymer.10. The fibrinogen composition of claim 7 , wherein the carrier material further comprises a swelling agent.11. The fibrinogen composition of claim 1 , wherein the fibrinogen composition is at least partially dehydrated.12. A fibrinogen composition ...

CELL PREPARATIONS FOR EXTEMPORANEOUS USE, USEFUL FOR HEALING AND REJUVENATION IN VIVO

The present invention relates to new plasma or new platelet-rich plasma preparations, new cell dissociation methods, new cell associations or compositions, a method of preparation thereof, a use thereof, devices for the preparation thereof and preparations containing such a platelet-rich plasma preparation and cell associations or compositions. Specifically, the invention provides plasma or platelet-rich plasma alone or in cell composition preparations for use in tissue regeneration and bone regeneration and pain reduction. 130-. (canceled)31. A sterilized , vacuum sealed separator tube for preparing a therapeutic platelet concentrate from whole blood comprising:an inlet adapted to introduce whole blood;an anticoagulant composition comprising either: (i) a sodium citrate solution; or (ii) anhydrous sodium citrate; anda thixotropic gel selected from a polyester-based gel or a polymer mixture gel, the thixotropic gel being water insoluble and chemically inert to blood constituents;{'sup': '12', 'wherein the separator tube is adapted to be centrifuged when at least partially filled with the whole blood, at about 1,500 g up to about 2,000 g for about 3 to about 10 minutes in a single centrifugation to separate blood components in the whole blood into at least: (i) the therapeutic platelet concentrate obtained without supernatant removal and containing greater than 300 billion platelets per liter and less than about 0.6×10red blood cells per liter; and (ii) red blood cells.'}32. The separator tube according to claim 31 , wherein the anticoagulant composition comprises a 0.1 M sodium citrate solution.33. The separator tube according to claim 31 , wherein the anticoagulant composition comprises anhydrous sodium citrate.34. The separator tube according to claim 31 , wherein the thixotropic gel is a polyester-based gel.35. The separator tube according to claim 31 , wherein the separator tube is comprised at least of polyethylene terephthalate (PET).36. (canceled)37. ( ...

TISSUE TREATMENT COMPOSITION COMPRISING FIBRIN OR FIBRINOGEN AND BIODEGRADABLE AND BIOCOMPATIBLE POLYMER

ФОРМОВАННЫЙ ПЛАСТИНЧАТЫЙ ПРОДУКТ И ГЕМОСТАТИЧЕСКИЙ МАТЕРИАЛ

1. Формованный пластинчатый продукт из полимерной композиции, содержащий по меньшей мере один белок, выбранный из группы, состоящей из фибриногена и тромбина, и по меньшей мере один полимер, выбранный из группы, состоящей из алифатического полиэфира и водорастворимого полимера.2. Формованный пластинчатый продукт по п. 1, где по меньшей мере один полимер, выбранный из группы, состоящей из алифатического полиэфира и водорастворимого полимера, выбран из группы, состоящей из производного целлюлозы, полимера, содержащего N-виниловую циклическую лактамную единицу, полиэтиленоксида, поливинилового спирта, гиалуроновой кислоты, декстрана, пуллулана, крахмала, и их смеси.3. Формованный пластинчатый продукт по п. 1, где по меньшей мере один полимер, выбранный из группы, состоящей из алифатического полиэфира и водорастворимого полимера, выбран из группы, состоящей из гидроксипропилцеллюлозы, метилцеллюлозы, гидроксиэтилцелллюлозы, гидроксипропилметилцеллюлозы, карбоксиметилцеллюлозы натрия, и их смеси.4. Формованный пластинчатый продукт по п. 1, где по меньшей мере один полимер, выбранный из группы, состоящей из алифатического полиэфира и водорастворимого полимера, выбран из группы, состоящей из полигликолевой кислоты, полимолочной кислоты, поликапролактона, их сополимера, и их смеси.5. Формованный пластинчатый продукт по любому из пп. 1-4, где формованный пластинчатый продукт является формованным пленочным продуктом или формованным волокнистым продуктом.6. Ламинированный формованный пластинчатый продукт, содержащий первый слой полимерной композиции, состоящий из фибриногена и водорастворимого полимера, и второй слой полимерной композиции, со РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (51) МПК A61L 24/00 (13) 2014 150 544 A (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ЗАЯВКА НА ИЗОБРЕТЕНИЕ (21)(22) Заявка: 2014150544, 13.05.2013 (71) Заявитель(и): ТЕЙДЗИН ЛИМИТЕД (JP), ТЕЙДЗИН ФАРМА ЛИМИТЕД (JP) Приоритет(ы): (30) Конвенционный приоритет: JP JP JP JP JP 2012- ...

DEPOTZUBEREITUNG

Antimicrobial compositions

FIBRINOGENKONZENTRATE FROM BLOOD PLASMA, PROCEDURE AND PLANT FOR YOUR PRODUCTION

BLUTSTILLENDE MULTILEVEL BANDAGE, WHICH ONE THROMBINSCHICHT BETWEEN TWO FIBRINOGENSCHICHTEN CONTAINS

DEPOT PREPARATION

Fibrin microbeads and uses thereof

Flexible wound covering based on fibrin and process for its production

DEPOT FORMULATIONS

Tissue sealant in which collagen and fibrin are mixed, and method for preparing same

The present invention relates to a tissue sealant in which collagen and fibrin are mixed and to a method for preparing same. To this end, the method of the present invention comprises the steps of: mixing a first material using fibrinogen and aprotinin; mixing a second material using thrombin, calcium chloride, and collagen; and preparing a third material by mixing the first material and the second material. The tissue sealant prepared by the method may supplement weaknesses, i.e. strength and degradability, of the fibrin sealant which is currently available in the commercial marketplace. Further, the tissue sealant of the present invention is cytophilic and activates blood platelets contained in blood so as to induce tissue regeneration. Thus, quality and reliability of products can be significantly improved so as to satisfy various needs of consumers who are users, thereby presenting good image.

METHODS, COMPOSITIONS AND KITS FOR REDUCING TISSUE ADHESIONS

The present invention provides a composition, comprising: proaccelerin (factor V) and at least one factor selected from the group consisting of: prothrombin (factor II), proconvertin (factor VII), and Stuart-Prower factor (factor X), wherein an amount of the proaccelerin in the composition is between 75% to 750% compared to an amount of proaccelerin in a blood plasma, and wherein an amount of the at least one factor is from 150% to 3000% compared to an amount of the at least one factor in the blood plasma; wherein the amount of proaccelerin and the at least one factor in the composition is determined by extrapolating an observed activity of the composition at a concentration of 500mM NaCl, using a prothrombin complementation assay using a standard curve constructed using the blood plasma.

PROCESS OF MAKING FLOWABLE HEMOSTATIC COMPOSITIONS AND DEVICES CONTAINING SUCH COMPOSITIONS

The present invention is directed to processes of making flowable hemostatic compositions and devices that include the flowable hemostatic composition disposed therein, where a volume of biocompatible liquid, a volume of a biocompatible gas, and an amount of solid particles of a biocompatible polymer are mixed together to form a substantially homogenous composition including a discontinuous gas phase and the solid particles substantially homogenously dispersed throughout a continuous liquid phase to form a flowable hemostatic composition, and the composition then transferred into a device suitable for applying the flowable hemostatic composition to a site of a body requiring hemostasis under conditions effective to maintain the substantially homogenous dispersion of the gas phase and the solid particles throughout the liquid phase.

SOLID DRESSING FOR TREATING WOUNDED TISSUE

Disclosed are solid dressings for treated wounded tissue in mammalian patients, such as a human, comprising a haemostatic layer consisting essentially of a fibrinogen component and a fibrinogen activator, wherein the haemostatic layer(s) is cast or formed from a single aqueous solution containing the fibrinogen component and the fibrinogen activator. Also disclosed are methods for treating wounded tissue using these dressings and frozen compositions useful for preparing the haemostatic layer(s) of these dressings.

MULTILAYERED BLOOD PRODUCT

A blood product (10), a method for preparing the blood product, a blood product obtainable by the method and a blood product preparing container means. The blood product comprises components from whole blood, especially fibrin, thrombocytes and leukocytes. The blood product (10) comprises a first layer (21), a second layer (22) and a third layer (23). The second layer (22) is adjacent to the first layer (21) and the third layer (23). The first layer (21) defines a first outer surface (24) of the blood product (10) and the third layer (23) defining a second outer surface (25) of the blood product (10). The first layer (21) comprises a majority of fibrin, the second layer (22) comprises a majority of thrombocytes and the third layer (23) comprises a majority of leukocytes.

TISSUE SEALANT AND GROWTH FACTOR CONTAINING COMPOSITIONS THAT PROMOTE ACCELERATED WOUND HEALING

... 2097063 9209301 PCTABS00013 This invention provides a growth factor-supplemented tissue sealant and methods for using said sealant to promote wound healing, endothelialization of vascular protheses, and the in vitro proliferation and differentiation of animal cells. In particular, this invention provides fibrin glue that is supplemented with at least one growth factor, such as a heparin binding growth factor and/or bone morphogenic proteins. The particular growth factor or factors selected is a function of its use.

BIOLOGICAL GLUE AND USE THEREOF AS MEDICINE

MATERIALS IN THE FORM OF NETWORKS INTERPENETRATE POLYMERS ASSOCIATING A FIBRIN GEL AND A POLYETHYLENE GLYCOL NETWORK

La présente invention se rapporte à un procédé de préparation d'un matériau sous forme de réseau interpénétré de polymères (RIP) associant un gel physique de fibrine et un réseau de polyéthylène (PEG). Elle se rapporte également aux matériaux susceptibles d'être obtenus par ce procédé ainsi que leur utilisation comme pansement pour les plaies, pansement chirurgical, comme un dispositif pour livrer des agents thérapeutiques, comme revêtement pour des dispositifs médicaux comme par exemple des stents, valves pour le coeur, des cathéters, des filtres prosthétiques vasculaires etc. Lesdits matériaux peuvent également être utilisés pour des cultures de cellules eucaryotes, ou encore comme support de molécules actives comme les antibiotiques ou les enzymes.

tissue sealant of collagen and fibrin Mixed and method of manufacturing the same

PRODUCT COMPRISING BOUND FIBRINOGEN AND THROMBIN FOR USE IN WOUND THERAPY OR SURGICAL REPAIR

A product comprises thrombin and microparticles having bound fibrinogen, as a combined preparation for simultaneous use in wound therapy or surgical repair. Another aspect lies in the use o insoluble microparticles having fibrinogen bound thereto, for the manufacture of a medicament for use in wound therapy or surgical repair of a patient having an abnormally low level of platelets.

ANTIMICROBIAL SUPERABSORBENT COMPOSITIONS

A composition has an enzyme that is able to convert a substrate to release hydrogen peroxide; a substrate for the enzyme; and a superabsorbent component, such as a superabsorbent polymer. The composition is in the form of a powder and may form a gel on contact with water.

COMPOSITION AND METHOD OF CREATING, REGENERATING AND REPAIRING TISSUES USING A CELL-CARRYING BIOLOGICAL IMPLANT WHICH IS ENRICHED WITH A PLATELET CONCENTRATE AND SUPPLEMENTS

A medium for human cells growing characterized by containing human serum and growth factors, and a method of growing human cells characterized by inoculating the medium with human cells and then growing the cells therein.

Fibrin foam and process

Sealant formulation and uses thereof

The present invention relates to a sealant formulation comprising a blend containing fibrinogen and an exogenous activator of a member of a mammalian blood clotting cascade.

Products comprising fibrinogen for use in therapy

HEMOSTATIC COMPOSITIONS CONTAINING STERILE THROMBIN

The present invention includes sterilized hemostatic compositions that contain a continuous, biocompatible liquid phase having a solid phase of particles of a biocompatible polymer suitable for use in hemostasis and that is substantially insoluble in the liquid phase, and sterile thrombin, each of which is substantially homogenously dispersed throughout the continuous liquid phase, and methods for making such compositions.

TISSUE TREATMENT COMPOSITION COMPRISING FIBRIN OR FIBRINOGENAND BIODEGRADABLE AND BIOCOMPATIBLE POLYMER

A tissue treatment composition, especially an adhesive composition is provided herein. Such tissue treatment composition comprises a biological adhesive, e.g., fibrin or fibrinogen, and a biodegradable and biocompatible viscosity-enhancing polymer which is capable of forming a viscous aqueous solution.

TISSUE SEALANT IN WHICH COLLAGEN AND FIBRIN ARE MIXED, AND METHOD FOR PREPARING SAME

Sealant formulations and uses thereof

IONIC LIQUIDS THAT STERILIZE AND PREVENT BIOFILM FORMATION IN SKIN WOUND HEALING DEVICES

Compositions for enhancing wound healing are disclosed herein. Also disclosed are methods of making the compositions and methods of using the compositions for the prevention of biofilm formation and for the inhibition of pathogen growth and proliferation. 1. A wound care composition , comprising:an ionic liquid (IL), wherein the ionic liquid is an antimicrobial, and wherein the ionic liquid is present in an amount of about 0.01% w/w to about 99% w/w; anda protein scaffold.2. The wound care composition of claim 1 , wherein the IL comprises a deep eutectic solvent (DES).3. The wound care composition of claim 1 , wherein the wound care composition is incorporated with or impregnated into or coated onto a wound dressing claim 1 , a bandage claim 1 , a gauze claim 1 , a patch claim 1 , a pad claim 1 , tape claim 1 , or a wrap.4. The wound care composition of claim 1 , wherein the ionic liquid comprises choline geranate (CAGE).5. The wound care composition of claim 1 , wherein the ionic liquid is present in an amount of about 40% w/w.6. The wound care composition of claim 1 , wherein the protein scaffold comprises a protein solution.7. The wound care composition of claim 6 , wherein the protein solution comprises collagen claim 6 , albumin claim 6 , casein claim 6 , fibrin claim 6 , fibroin claim 6 , gelatin claim 6 , keratin claim 6 , elastin claim 6 , tropoelastin claim 6 , or combinations thereof.8. The wound care composition of claim 1 , wherein the protein scaffold is electrospun.9. The wound care composition of claim 1 , wherein the protein scaffold is present in an amount of about 1% w/v to about 20% w/v.10. The wound care composition of claim 1 , wherein the protein scaffold is present in an amount of about 10% w/v.11. The wound care composition of claim 1 , comprising about 0.2% w/w choline geranate (CAGE) and about 10% w/v gelatin.12. A wound dressing comprising:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'a wound care composition of ; and'}a wound ...

CONCENTRATE OF FIBRINOGENE OBTAINED FROM BLOOD PLASMA, PROCESS AND PLANT FOR ITS PREPARATION

CELL PREPARATIONS FOR EXTEMPORANEOUS USE, USEFUL FOR HEALING AND REJUVENATION IN VIVO

СОСТАВЫ ДЛЯ ЛЕЧЕНИЯ РАН

1. Фармацевтическая композиция, содержащая рассасывающийся носитель из биосовместимого биоразлагаемого полимера и диспергированные, по меньшей мере частично, в объеме указанного рассасывающегося носителя или на его поверхности микрочастицы, содержащие фибриноген в количестве примерно 0,1-15 мг/см, или микрочастицы, содержащие тромбин в количестве от примерно 0,01 до 500 МЕ/см, при этом микрочастицы дополнительно содержат стеклообразный носитель.2. Фармацевтическая композиция по п. 1, отличающаяся тем, что диспергированные, по меньшей мере частично, в объеме указанного рассасывающегося носителя или на его поверхности, микрочастицы представляют собой смесь микрочастиц, содержащих фибриноген, и микрочастиц, содержащих тромбин.3. Фармацевтическая композиция по п. 1 или 2, отличающаяся тем, что стеклообразный носитель из микрочастиц содержит трегалозу.4. Фармацевтическая композиция по п. 3, отличающаяся тем, что микрочастицы зафиксированы на поверхности или зафиксированы в объеме указанного рассасывающегося носителя.5. Фармацевтическая композиция по п. 1 или 2, отличающаяся тем, что рассасывающийся носитель является эластичным или пористым, и указанная композиция необязательно дополнительно содержит пластификатор, связующий агент или увеличивающий вязкость агент.6. Фармацевтическая композиция по п. 5, отличающаяся тем, что рассасывающийся носитель является одновременно эластичным и пористым.7. Фармацевтическая композиция по п. 1 или 2, отличающаяся тем, что рассасывающийся носитель содержит биосовместимый полимер, выбранный из группы, состоящей из полисахаридов, альбумина, целлюлозы, метилцеллюлозы, алкилгидрокси� РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (13) 2013 155 713 A (51) МПК A61K 9/16 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ЗАЯВКА НА ИЗОБРЕТЕНИЕ (21)(22) Заявка: 2013155713/15, 06.06.2012 (71) Заявитель(и): ПРОФИБРИКС БВ (NL) Приоритет(ы): (30) Конвенционный приоритет: 06.07.2011 EP 11172945.5 (85) Дата начала рассмотрения заявки PCT на ...

Formulations for wound therapy

The present invention relates to novel formulations comprising a dry powder fibrin sealant comprised a mixture of fibrinogen and/or thrombin, for use in the treatment of wounds or injuries, in particular for use as a topical hemostatic composition or for surgical intervention.

Depot formulations

PRODUCTS COMPRISING FIBRINOGEN FOR USE IN THERAPY

A product comprises thrombin and microparticles having bound fibrinogen, as a combined preparation for simultaneous use in wound therapy or surgical repair. Another aspect lies in the use of insoluble microparticles having fibrinogen bound thereto, for the manufacture of a medicament for use in wound therapy or surgical repair of a patient having an abnormally low level of platelets.

WOUND-TREATING ABSORBENT

The present disclosure provides wound-treating absorbent kits that comprise a set of hemostatic compositions including at least (1) a first hemostatic composition including a first crosslinked polysaccharide selected from the group consisting of cyclodextrin and dextran, and (2) a second hemostatic composition including a second crosslinked polysaccharide selected from the group consisting of cyclodextrin and dextran. In some embodiments, the first hemostatic composition has a first degree of crosslinking, and the second hemostatic composition has a second degree of crosslinking higher than the first degree of crosslinking. Also provided are methods of treating a wound by selecting a hemostatic composition from the disclosed set of hemostatic compositions, and administering the selected hemostatic composition to a site of the wound.

HEMOSTATIC PRODUCTS

A hemostatic product that includes a fibrinogen mixture, a thrombin mixture and a biologically tolerable liquid. The fibrinogen mixture includes fibrinogen and at least one fibrinogen stabilizer. The thrombin mixture includes thrombin and at least one thrombin stabilizer. The biologically tolerable liquid is mixed with the fibrinogen mixture and the thrombin mixture to form the hemostatic product.

Wound healing device

A plasma coating device for treating a wound comprises a plasma chamber having: one or more electrodes, a gas supply inlet, a plasma outlet exposed to ambient pressure, and an ignition system operatively connected to the electrodes for providing a non-thermal equilibrium plasma within the plasma chamber. An aerosol delivery system is operable to introduce a bioresorbable material as an aerosol into the plasma, to produce a coating on the wound surface.

WOUND-TREATING ABSORBENT

The present disclosure provides wound-treating absorbent kits that comprise a set of hemostatic compositions including at least (1) a first hemostatic composition including a first crosslinked polysaccharide selected from the group consisting of cyclodextrin and dextran, and (2) a second hemostatic composition including a second crosslinked polysaccharide selected from the group consisting of cyclodextrin and dextran. In some embodiments, the first hemostatic composition has a first degree of crosslinking, and the second hemostatic composition has a second degree of crosslinking higher than the first degree of crosslinking. Also provided are methods of treating a wound by selecting a hemostatic composition from the disclosed set of hemostatic compositions, and administering the selected hemostatic composition to a site of the wound. 1. A wound-treating absorbent kit comprising:a set of hemostatic compositions including at least (1) a first hemostatic composition including a first crosslinked polysaccharide selected from the group consisting of cyclodextrin and dextran, wherein the first hemostatic composition has a first degree of crosslinking, and (2) a second hemostatic composition including a second crosslinked polysaccharide selected from the group consisting of cyclodextrin and dextran, wherein the second hemostatic composition has a second degree of crosslinking higher than the first degree of crosslinking.2. The wound-treating absorbent kit of claim 1 , wherein each of the first and second hemostatic compositions includes crosslinked β-cyclodextrin.3. The wound-treating absorbent kit of claim 1 , wherein each of the first and second hemostatic compositions is in powdered form.4. The wound-treating absorbent kit of comprising a pharmaceutically acceptable diluent for reconstitution of any of the first and second hemostatic compositions.5. The wound-treating absorbent kit of claim 1 , wherein each of the first and second hemostatic compositions comprises a ...

Solid dressing for treating wounded tissue and processes for mixing fibrinogen and thrombin while preserving fibrin-forming ability, compositions produced by these processes, and the use thereof

Fibrin Sealant products are used for topical hemostasis and tissue adherence. They are composed of two main reagents, fibrinogen and thrombin. When mixed in solution fibrinogen is converted to fibrin upon the addition of activated thrombin. Therefore typically these two components are stored separately in a lyophilized or liquid state, and mixed, upon or immediately before, application to a patient. While effective, these products require significant preparation that must take place immediately before application, thus delaying treatment and limiting the use of these haemostatic products to the treatment of mild forms of low pressure and low volume bleeding. Attempts to eliminate this delay and expand the usefulness and effectiveness of these products have resulted in products produced by processes that require the separation of these components and their deposition in distinct layers within the product. The processes described herein permit the mixing of fibrinogen and thrombin during product manufacture, without excessive fibrin formation. The resulting ‘pre-mixed’ fibrin sealant material can then be stored in either a frozen or dried state, or suspended in a non-aqueous environment. Activation of the material to form therapeutic fibrin sealant is accomplished by permitting the product to thaw (if frozen) or by the addition of water or other aqueous fluid, including blood, or other bodily fluids, if dried or suspended in a non-aqueous environment. The resulting material can be used to make a product in which a pre-mixed form of activatable fibrin sealant is a desired component.

IONIC LIQUIDS THAT STERILIZE AND PREVENT BIOFILM FORMATION IN SKIN WOUND HEALING DEVICES

Compositions for enhancing wound healing are disclosed herein. Also disclosed are methods of making the compositions and methods of using the compositions for the prevention of biofilm formation and for the inhibition of pathogen growth and proliferation. 1. A wound care composition , comprising:an ionic liquid (IL) and a neutral species, wherein the ionic liquid is present in an amount of about 0.01% w/w to about 99% w/w; anda protein scaffold comprising a protein solution.2. The wound care composition of claim 1 , wherein the IL is choline geranate (CAGE) or choline citronellate.3. The wound care composition of claim 1 , wherein the wound care composition is incorporated with or impregnated into or coated onto a wound dressing claim 1 , a bandage claim 1 , a gauze claim 1 , a patch claim 1 , a pad claim 1 , tape claim 1 , or a wrap.4. The wound care composition of claim 1 , wherein the ionic liquid is present in an amount of about 40% w/w.5. The wound care composition of claim 1 , wherein the protein solution comprises collagen claim 1 , albumin claim 1 , casein claim 1 , fibrin claim 1 , fibroin claim 1 , gelatin claim 1 , keratin claim 1 , elastin claim 1 , tropoelastin claim 1 , or combinations thereof.6. The wound care composition of claim 1 , wherein the protein scaffold is electrospun.7. The wound care composition of claim 1 , wherein the protein solution is present in an amount of about 1% w/v to about 20% w/v.8. The wound care composition of claim 1 , wherein the protein scaffold is present in an amount of about 10% w/v.9. The wound care composition of claim 1 , comprising IL in an amount of about 0.2% w/w and gelatin in an amount of about 10% w/v gelatin.10. The wound care composition of claim 1 , wherein the neutral species comprises farnesol claim 1 , linalool claim 1 , carvacrol claim 1 , geranic acid claim 1 , citronellic acid claim 1 , cinnamaldehyde claim 1 , eugenol claim 1 , or combinations thereof.11. The wound care composition of claim 1 , ...

METHODS OF MAKING FIBRIN COMPOSITIONS AND ARTICLES

A method of forming a fibrin hydrogel composition including providing one or more unitary masses of a fibrin hydrogel, dividing at least one of the unitary masses of the fibrin hydrogel into a multiplicity of smaller pieces of the fibrin hydrogel, and recombining at least a portion of the smaller pieces into a cohesive mass. Dividing at least one of the unitary masses of fibrin hydrogel into a multiplicity of smaller pieces may include shearing or cutting the unitary masses to form an aqueous dispersion of the fibrin hydrogel in an aqueous medium. The aqueous dispersion of fibrin hydrogel may be applied to a substrate on a roller or an endless belt, and is optionally overlaid by a scrim. The cohesive mass of fibrin hydrogel, which may be formed by removing at least a portion of the aqueous medium from the aqueous dispersion of the smaller pieces of the fibrin hydrogel, finds uses in wound dressing articles. 1. A method of forming a fibrin hydrogel composition comprisingproviding one or more unitary masses of a fibrin hydrogel comprising fibrin;dividing at least one of the unitary masses of the fibrin hydrogel into a plurality of smaller pieces of the fibrin hydrogel;recombining at least a portion of the smaller pieces into a cohesive mass, optionally wherein the cohesive mass is on a substrate.2. The method of claim 1 , wherein dividing at least one of the unitary masses of the fibrin hydrogel into a plurality of smaller pieces of the fibrin hydrogel comprises shearing the one or more unitary masses of the fibrin hydrogel to form an aqueous dispersion of the smaller pieces of the fibrin hydrogel in an aqueous medium.3. The method of claim 2 , further comprising adding an aqueous liquid to the one or more unitary masses of the fibrin hydrogel.4. The method of claim 1 , wherein the smaller pieces of the fibrin hydrogel exhibit a particle size of no greater than 5 mm.5. The method of claim 3 , wherein the one or more unitary masses of the fibrin hydrogel comprise a ...

Cell Preparations For Extemporaneous Use, Useful For Healing And Rejuvenation In Vivo

The present invention relates to new plasma or new platelet-rich plasma preparations, new cell dissociation methods, new cell associations or compositions, a method of preparation thereof, a use thereof, devices for the preparation thereof and preparations containing such a platelet-rich plasma preparation and cell associations or compositions. Specifically, the invention provides plasma or platelet-rich plasma alone or in cell composition preparations for use in tissue regeneration and bone regeneration and pain reduction. 1. A method of treating a patient with platelet rich plasma , the method comprising:withdrawing blood from the patient;centrifuging the blood in a centrifugation tube containing a thixotropic gel and an anticoagulant, the thixotropic gel being configured to separate platelet rich plasma, the centrifuging being performed for a length of time such that the thixotropic gel forms a barrier between plasma and erythrocytes;removing the platelet rich plasma from the tube; andadministering the platelet rich plasma to the patient.2. The method of claim 1 , wherein said centrifuging comprises centrifuging the tube at a force between about 1500 g and about 2000 g for about 3 to 10 minutes.3. The method of claim 1 , wherein said centrifuging comprises centrifuging the tube at a force of at least 1500 g for at least 8 minutes.4. The method of claim 1 , further comprising separating the platelet rich plasma by removing approximately half of a supernatant containing platelet poor plasma.5. The method of claim 4 , further comprising re-suspending the platelet rich plasma in the tube claim 4 , wherein said re-suspending follows said separating the platelet rich plasma.6. The method of claim 1 , further comprising admixing the platelet rich plasma with a coagulation activator claim 1 , wherein the coagulation activator comprises at least one of: a thrombin activator claim 1 , a fibrinogen activator claim 1 , a calcium claim 1 , a calcium salt claim 1 , a CaCl ...

Fibrinogen composition, method and wound articles

Provided is a method of forming a fibrinogen hydrogel composition, the method including providing a fibrinogen hydrogel or precursor thereof, comprising fibrinogen hydrogel forming salt. The fibrinogen hydrogel forming salt concentration is greater than or equal to the threshold concentration to form a fibrinogen hydrogel. The method further includes denaturing the fibrinogen hydrogel such as by heating. The method optionally further includes combining the fibrinogen hydrogel with a carrier material. When present, the concentration of the carrier material typically ranges from 0.1 to about 50 wt.-%. The method further includes reducing the salt concentration below the threshold concentration to form a fibrinogen hydrogel.

Cell Preparations For Extemporaneous Use, Useful For Healing And Rejuvenation In Vivo

The present invention relates to new plasma or new platelet-rich plasma preparations, new cell dissociation methods, new cell associations or compositions, a method of preparation thereof, a use thereof, devices for the preparation thereof and preparations containing such a platelet-rich plasma preparation and cell associations or compositions. Specifically, the invention provides plasma or platelet-rich plasma alone or in cell combinations preparations for use in tissue regeneration and bone regeneration and pain reduction. 1. A medical separator system for preparation of a platelet concentrate , comprising: a thixotropic gel being adapted to separate blood components in whole blood to provide a platelet concentrate containing less than or equal to 1% hematocrit and a pellet containing more than or equal to 99% hematocrit by forming a barrier between plasma and erythrocytes when said tube is centrifuged; and', 'an anticoagulant being adapted to at least reduce coagulation of said whole blood., 'a tube being adapted to be centrifuged for a length of time and containing two additives, wherein said two additives include2. The medical separator system of claim 1 , wherein said thixotropic gel is adapted to separate said blood components in said whole blood to provide said platelet concentrate containing 2 or more times a normal level of platelets and growth factors compared to said whole blood.3. The medical separator system of claim 2 , wherein said thixotropic gel is adapted to separate said blood components in said whole blood to provide said platelet concentrate with platelet recovery of 95%±5%.4. The medical separator system of claim 3 , wherein no other additives are contained in said tube.5. A kit comprising:{'claim-ref': {'@idref': 'CLM-00003', 'claim 3'}, 'a medical separator system of ; and'}an applicator device for applying said platelet concentrate to a patient for medical, therapeutic, or skincare application.6. The medical separator system of claim 3 , ...

FIBRIN COMPOSITION, METHOD AND WOUND ARTICLES

A method of forming a fibrin hydrogel composition is described. The method comprises forming an aqueous solution comprising fibrinogen, fibrin-forming enzyme, and a fibrin hydrogel forming salt. The fibrin hydrogel forming salt concentration is greater than or equal to the threshold concentration to form a fibrin hydrogel. The method further comprises reducing the salt concentration below the threshold concentration to form a fibrin hydrogel. In some embodiments, the aqueous solution further comprises a plasticizer. A fibrin composition is also described comprising a fibrin hydrogel having a fibrin concentration ranging from 0.1 to 10 wt-%; and a fibrin hydrogel forming salt. The fibrin hydrogel forming salt has a concentration less than a threshold concentration to form the fibrin hydrogel. The fibrin hydrogel or dehydrated fibrin hydrogel can be in various physical forms such a sheet, foam, or plurality of pieces. Also described are methods of forming a fibrin article, wound dressings and a method of treatment of a wound. 1. A method of forming a fibrin hydrogel composition comprisingforming an aqueous solution comprising fibrinogen, fibrin-forming enzyme, and a fibrin hydrogel forming salt; wherein the fibrin hydrogel forming salt has a concentration greater than or equal to the threshold concentration to form a fibrin hydrogel;reducing the salt concentration below the threshold concentration to form a fibrin hydrogel.2. The method of wherein the fibrin hydrogel forming salt comprises calcium salt.3. The method of wherein the threshold concentration of the aqueous solution is at least 0.45 wt %.4. The method of wherein the aqueous solution further comprises a plasticizer.5. The method of wherein the plasticizer comprises a sugar alcohol claim 4 , an alkane diol claim 4 , or a combination thereof.6. The method of wherein the solution further comprises a buffering agent.7. The method of further comprising forming the fibrin hydrogel into a sheet claim 1 , foam ...

Hemostatic products

A hemostatic product that includes a fibrinogen mixture, a thrombin mixture and a biologically tolerable liquid. The fibrinogen mixture includes fibrinogen and at least one fibrinogen stabilizer. The thrombin mixture includes thrombin and at least one thrombin stabilizer. The biologically tolerable liquid is mixed with the fibrinogen mixture and the thrombin mixture to form the hemostatic product.

Processes For Mixing Fibrinogen and Thrombin Under Conditions That Minimize Fibrin Formation While Preserving Fibrin-forming Ability, Compositions Produced by These Processes, and the Use Thereof

Fibrin Sealant products are used for topical hemostasis and tissue adherence. They are composed of two main reagents, fibrinogen and thrombin. When mixed in solution fibrinogen is converted to fibrin upon the addition of activated thrombin. Therefore typically these two components are stored separately in a lyophilized or liquid state, and mixed, upon or immediately before, application to a patient. While effective, these products require significant preparation that must take place immediately before application, thus delaying treatment and limiting the use of these haemostatic products to the treatment of mild forms of low pressure and low volume bleeding. Attempts to eliminate this delay and expand the usefulness and effectiveness of these products have resulted in products produced by processes that require the separation of these components and their deposition in distinct layers within the product. The processes described herein permit the mixing of fibrinogen and thrombin during product manufacture, without excessive fibrin formation. The resulting ‘pre-mixed’ fibrin sealant material can then be stored in either a frozen or dried state, or suspended in a non-aqueous environment. Activation of the material to form therapeutic fibrin sealant is accomplished by permitting the product to thaw (if frozen) or by the addition of water or other aqueous fluid, including blood, or other bodily fluids, if dried or suspended in a non-aqueous environment. The resulting material can be used to make a product in which a pre-mixed form of activatable fibrin sealant is a desired component. 1. A haemostatic composition comprising a frozen mixture of fibrinogen and thrombin , with or without Factor XIII , which contains insufficient fibrin to prohibit its effective use as a haemostatic agent , and which further retains the ability to convert sufficient fibrinogen to fibrin upon thawing to provide effective hemostasis.2. The composition of claim 1 , wherein the composition ...

USE OF PHOTOSYNTHETIC SCAFFOLDS IN TISSUE ENGINEERING

The present invention is concerned with a photosynthetic scaffold that delivers oxygen and its uses for tissue engineering and the treatment of ischemia. 1. A composition comprising photosynthetic cells.2. The composition of claim 1 , wherein the photosynthetic cells are algae cells.3. The composition of claim 2 , wherein the algae cells are unicellular algae cells.4Chlamydomonas.. The composition of claim 3 , wherein the unicellular algae cells are from the genus5ChlamydomonasChlamydomonas reinhardtii.. The composition of claim 4 , wherein the is6. The composition of claim 1 , wherein the photosynthetic cells are encapsulated with a permeable immunologically inert material.7. The composition of claim 6 , wherein the permeable immunologically inert material is a natural or synthetic polymer.8. The composition of claim 7 , wherein the natural or synthetic polymer is a hydrogel or alginate.9. The composition of claim 1 , wherein at least some of the photosynthetic cells are genetically engineered cells.10. The composition of claim 5 , wherein at least some of the photosynthetic cells have been genetically engineered to contain nucleic acids encoding for at least one bioactive molecule.11. The composition of claim 1 , for use ex vivo.12. The composition of claim 1 , for use in vivo.13. A composition comprising photosynthetic cells configured for use claim 1 , in a subject claim 1 , in a method selected from the group consisting of: treatment of hypoxia; treatment of ischemia claim 1 , in vivo implantation claim 1 , treatment or prevention of inflammation claim 1 , treatment of damage of tissue selected from skin claim 1 , nerve claim 1 , bone claim 1 , cartilage or blood tissue.14. The composition of claim 13 , for use ex vivo.15. The composition of claim 11 , for use in vivo. This application is a divisional of U.S. patent application Ser. No. 14/869,930, filed on Sep. 29, 2015, which is a continuation of U.S. patent application Ser. No. 13/636,402, filed on Dec. 20, ...

SOLID DRESSING FOR TREATING WOUNDED TISSUE AND PROCESSES FOR MIXING FIBRINOGEN AND THROMBIN WHILE PRESERVING FIBRIN-FORMING ABILITY, COMPOSITIONS PRODUCED BY THESE PROCESSES, AND THE USE THEREOF

Disclosed are solid dressings for treating wounded tissue in mammalian patients, such as a human, comprising a haemostatic layer consisting essentially of a fibrinogen component and a fibrinogen activator, wherein the haemostatic layer(s) is cast or formed from a single aqueous solution containing the fibrinogen component and the fibrinogen activator. Also disclosed are methods for treating wounded tissue using these dressings and frozen compositions useful for preparing the haemostatic layer(s) of these dressings. 1. A solid dressing for treating wounded tissue in a mammal , said solid dressing comprising at least one haemostatic layer having a wound facing surface and an opposite surface , and consisting essentially of fibrinogen and a solvent consisting of water and a fibrinogen activator , wherein said haemostatic layer is substantially homogenous , and wherein said fibrinogen is present in an amount about 13.0 mg/cmof the wound facing surface of said dressing , and wherein the moisture content of said solid dressing is from 6% to 44%.2. The solid dressing of claim 1 , further comprising at least one support layer.3. The solid dressing of claim 2 , wherein said support layer comprises a backing material.4. The solid dressing of claim 1 , wherein said haemostatic layer also contains a fibrin cross-linker and/or a source of calcium ions.5. The solid dressing of claim 1 , wherein said haemostatic layer also contains one or more of the following: at least one filler claim 1 , at least one solubilizing agent claim 1 , at least one foaming agent and at least one release agent.6. The solid dressing of claim 1 , wherein said haemostatic layer is cast as a single piece.7. The solid dressing of claim 1 , wherein said haemostatic layer is composed of a plurality of particles claim 1 , each of said particles consisting essentially of fibrinogen and thrombin.8. The solid dressing of claim 7 , wherein said haemostatic layer further contains at least one binding agent in an ...

Cell preparations for extemporaneous use, useful for healing and rejuvenation in vivo

The present invention relates to new plasma or new platelet-rich plasma preparations, new cell dissociation methods, new cell associations or compositions, a method of preparation thereof, a use thereof, devices for the preparation thereof and preparations containing such a platelet-rich plasma preparation and cell associations or compositions. Specifically, the invention provides plasma or platelet-rich plasma alone or in cell composition preparations for use in tissue regeneration and bone regeneration and pain reduction.

Techniques for treatment of abscesses

This document provides devices, system, and methods for treating an abscess cavity. For example, procedures that involve supplementing a biocompatible filler material with a therapeutic agent to promote tissue regeneration and healing are provided. The biocompatible filler materials that are treated with a therapeutic agent are implanted into the abscess cavity. The biocompatible filler material provides a tissue growth scaffold, and the therapeutic agent enhances tissue growth and healing.

Cell Preparations For Extemporaneous Use, Useful For Healing And Rejuvenation In Vivo

The present invention relates to new plasma or new platelet-rich plasma preparations, new cell dissociation methods, new cell associations or compositions, a method of preparation thereof, a use thereof, devices for the preparation thereof and preparations containing such a platelet-rich plasma preparation and cell associations or compositions. Specifically, the invention provides plasma or platelet-rich plasma alone or in cell composition preparations for use in tissue regeneration and bone regeneration and pain reduction. 1. A system for preparing a cell preparation , comprising: an anticoagulant;', 'a cap sealing the anticoagulant in the tube;, 'a tube havingthe tube adapted to centrifuge blood to form a platelet rich plasma;a container having hyaluronic acid;an applicator device adapted to administer to a patient a cell preparation including a mixture of the platelet rich plasma and the hyaluronic acid.2. The system of claim 1 , further comprising a thixotropic gel sealed in the tube claim 1 , the thixotropic gel separating the blood by forming a barrier between the platelet rich plasma and red blood cells when the tube is centrifuged for a length of time.3. The system of claim 2 , wherein:the thixotropic gel includes a polymer mixture;the anticoagulant includes a buffered sodium citrate solution at approximately 0.1 M.4. The system of claim 1 , wherein the applicator device comprises a double syringe mixing the platelet rich plasma and hyaluronic acid to form the cell preparation at a treatment site of the patient.5. The system of claim 1 , wherein the platelet rich plasma and the hyaluronic acid are mixed in the container.6. The system of claim 1 , wherein the container and the applicator device comprise the same device.7. The system of claim 1 , further comprising:phlebotomy accessories including a needle for drawing the blood from a patient;wherein the tube is sealed with the cap under vacuum pressure, the vacuum pressure helping to aspirate the blood from ...

Cell preparation for extemporaneous use, useful for healing and rejuvenation in vivo

The present invention relates to new plasma or new platelet-rich plasma preparations, new cell dissociation methods, new cell associations or compositions, a method of preparation thereof, a use thereof, devices for the preparation thereof and preparations containing such a platelet-rich plasma preparation and cell associations or compositions. Specifically, the invention provides plasma or platelet-rich plasma alone or in cell composition preparations for use in tissue regeneration and bone regeneration and pain reduction.

SOLID DRESSING FOR TREATING WOUNDED TISSUE

Disclosed are solid dressings for treated wounded tissue in mammalian patients, such as a human, comprising a haemostatic layer consisting essentially of a fibrinogen component and a fibrinogen activator, wherein the haemostatic layer(s) is cast or formed from a single aqueous solution containing the fibrinogen component and the fibrinogen activator. Also disclosed are methods for treating wounded tissue using these dressings and frozen compositions useful for preparing the haemostatic layer(s) of these dressings. 1. A solid dressing for treating wounded tissue in a mammal comprising at least one haemostatic layer consisting essentially of a fibrinogen component and a fibrinogen activator , wherein said haemostatic layer is formed from a single aqueous solution containing said fibrinogen component and said fibrinogen activator.2. A solid dressing for treating wounded tissue in a mammal comprising at least one haemostatic layer consisting essentially of a fibrinogen component and a fibrinogen activator , wherein said haemostatic layer is cast as a single piece.3. The solid dressing of or , further comprising at least one support layer.4. The solid dressing of claim 3 , wherein said support layer comprises a backing material.5. The solid dressing of claim 3 , wherein said support layer comprises an internal support material.6. The solid dressing of claim 3 , wherein said support layer comprises a resorbable material.7. The solid dressing of claim 3 , wherein said support layer comprises a non-resorbable material.8. The solid dressing of claim 7 , wherein said non-resorbable material is selected from the group consisting of silicon polymers claim 7 , paper claim 7 , gauze and latexes.9. The solid dressing of claim 3 , further comprising at least physiologically acceptable adhesive between said haemostatic layer and said backing layer.10. The solid dressing of claim 6 , wherein said resorbable material is selected from the group consisting of proteinaceous materials and ...

Method for attaching body tissues and kit for preparing tissue adhesive used for the same, and device for tissue adhesion

To provide a means which can suppress a decrease in the effect of preventing enzyme leakage and a decrease in adhesive strength (pressure resistance) when attaching body tissues by using a tissue adhesive containing a protein. A method for attaching body tissues by applying a tissue adhesive containing a protein to the body tissues includes a heat treatment of the protein simultaneously with or after applying the tissue adhesive to the body tissues.

Fenestrated Hemostatic Patch

A hemostat comprises a non-porous patch made of a bio-resorbable tissue compatible material, said patch having a tissue-facing surface and a top surface; an optional hemostatic agent that is disposed on said tissue-facing surface or optionally dispersed throughout said patch or optionally as a separate carrier layer, and at least one aperture or slit that penetrates said patch at least partially from said tissue-facing surface to said top surface. 117-. (canceled)18. A method of use of a hemostatic device , comprising the steps of:providing a non-porous patch made of a bio-resorbable tissue compatible material, said patch having a tissue-facing surface and a top surface;providing an optional hemostatic agent that is disposed on said tissue-facing surface or optionally dispersed throughout said patch or optionally as a separate carrier layer, said patch having at least one aperture or slit or combinations thereof that penetrate said patch at least partially from said tissue-facing surface to said top surface, and applying said patch to a bleeding tissue or to a bleeding wound.19. (canceled) The present invention relates generally to agents and devices for promoting hemostasis and, more particularly, to hemostatic patches comprising biological factors disposed on or within absorbable scaffolds.Prolonged or uncontrolled bleeding following trauma or after surgery of the cardiovascular system, liver, kidney, spleen, and other organs is a serious complication associated with significant morbidity, mortality, and cost of care. Meticulous surgical technique is essential for primary hemostasis, but when conventional techniques such as compression, ligation, clipping, and electrocautery are impractical or ineffective, topical hemostatic agents are indispensable and relied upon to help control blood loss.The control of bleeding is essential and critical in surgical procedures to minimize blood loss, to reduce post-surgical complications, and to shorten the duration of the ...

IONIC LIQUIDS THAT STERILIZE AND PREVENT BIOFILM FORMATION IN SKIN WOUND HEALING DEVICES

Compositions for enhancing wound healing are disclosed herein. Also disclosed are methods of making the compositions and methods of using the compositions for the prevention of biofilm formation and for the inhibition of pathogen growth and proliferation. 1. An electrospun wound care composition , comprising:an ionic liquid (IL), wherein the ionic liquid is choline geranate (CAGE), and wherein the ionic liquid is present in an amount of about 0.01% w/w to about 60% w/w; anda protein solution comprising collagen, agarose, albumin, alginate, casein, fibrin, fibroin, gelatin, keratin, pectin, elastin, tropoelastin, cellulose, chitosan, chitin, or combinations thereof,wherein the ionic liquid is electrospun with the protein solution.2. The wound care composition of claim 1 , wherein the ionic liquid is present in an amount ranging from about 0.01% w/w to about 40% w/w.3. The wound care composition of claim 2 , wherein the ionic liquid is present in an amount of ranging from about 0.01% w/w to about 20% w/w.4. The wound care composition of claim 2 , wherein the ionic liquid is present in an amount of about 0.2% w/w.5. The wound care composition of claim 2 , wherein the protein solution is present in an amount of about 1% w/v to about 20% w/v.6. The wound care composition of claim 2 , wherein the protein solution is present in an amount of about 10% w/v.7. The wound care composition of claim 2 , comprising about 0.2% w/w choline geranate (CAGE) and about 10% w/v protein solution.8. The wound care composition of claim 2 , wherein the wound care composition is incorporated with or impregnated into or coated onto a wound dressing claim 2 , a bandage claim 2 , a gauze claim 2 , a patch claim 2 , a pad claim 2 , tape claim 2 , or a wrap.9. A wound dressing comprising:{'claim-ref': {'@idref': 'CLM-00002', 'claim 2'}, 'a wound care composition of ; and'}a wound dressing material.10. The wound dressing of claim 9 , wherein the wound dressing material is a bandage claim 9 , a wipe ...

BIOLOGICAL GLUE AND USE THEREOF AS A MEDICAMENT

Disclosed is a thrombin-free, liquid biological glue for therapeutic use, including fibrinogen and factor VIIa. The ratio of fibrinogen concentration to FVIIa concentration is 20000:1 to 1000:1, with the concentrations being expressed in weight per volume. The fibrinogen concentration is lower than 60 mg/ml. Also disclosed are a kit for preparing such a biological glue, a method to prepare the glue, and a medicament. 126-. (canceled)27. Thrombin-free , liquid biological glue for therapeutic use , comprising fibrinogen and factor VIIa , wherein the ratio of fibrinogen concentration to FVIIa concentration is 20000:1 to 1000:1 , with the concentrations being expressed in weight per volume , and wherein the fibrinogen concentration is lower than 60 mg/ml.28. The biological glue according to claim 27 , having a fibrinogen content of 0.1 mg to 45 mg per ml of biological glue.29. The biological glue according to claim 27 , having a FVIIa content of 0.1 μg to 10 μg per ml of biological glue.30. The biological glue according to claim 27 , comprising a source of calcium ions.31. The biological glue according to claim 30 , comprising 2 μmoles to 30 μmoles of the calcium ion source per ml of biological glue.32. The biological glue according to claim 27 , further comprising at least one gelling agent.33. A therapeutic method comprising administering a thrombin-free claim 27 , liquid biological glue comprising fibrinogen claim 27 , factor VIIa and at least one gelling agent.34. The therapeutic method according to claim 33 , wherein the biological glue has a fibrinogen content lower than 60 mg/ml.35. The therapeutic method according to claim 33 , wherein the biological glue has a FVIIa content of 0.1 μg to 10 μg per ml of biological glue.36. The therapeutic method according to wherein the biological glue comprises a source of calcium ions.37. The biological glue according to claim 32 , wherein said at least one gelling agent is a cellulose derivative.38. The biological glue ...

IONIC LIQUIDS THAT STERILIZE AND PREVENT BIOFILM FORMATION IN SKIN WOUND HEALING DEVICES

Compositions for enhancing wound healing are disclosed herein. Also disclosed are methods of making the compositions and methods of using the compositions for the prevention of biofilm formation and for the inhibition of pathogen growth and proliferation. 1. An electrospun wound care composition , comprising:an ionic liquid (IL), wherein the ionic liquid is choline geranate (CAGE), and wherein the ionic liquid is present in an amount of about 0.01% w/w to about 60% w/w; anda protein solution comprising collagen, agarose, albumin, alginate, casein, fibrin, fibroin, gelatin, keratin, pectin, elastin, tropoelastin, cellulose, chitosan, chitin, or combinations thereof,wherein the ionic liquid is electrospun with the protein solution.2. The wound care composition of claim 1 , wherein the ionic liquid is present in an amount ranging from about 0.01% w/w to about 40% w/w.3. The wound care composition of claim 2 , wherein the ionic liquid is present in an amount of ranging from about 0.01% w/w to about 20% w/w.4. The wound care composition of claim 2 , wherein the ionic liquid is present in an amount of about 0.2% w/w.5. The wound care composition of claim 2 , wherein the protein solution is present in an amount of about 1% w/v to about 20% w/v.6. The wound care composition of claim 2 , wherein the protein solution is present in an amount of about 10% w/v.7. The wound care composition of claim 2 , comprising about 0.2% w/w choline geranate (CAGE) and about 10% w/v protein solution.8. The wound care composition of claim 2 , wherein the wound care composition is incorporated with or impregnated into or coated onto a wound dressing claim 2 , a bandage claim 2 , a gauze claim 2 , a patch claim 2 , a pad claim 2 , tape claim 2 , or a wrap.9. A wound dressing comprising:{'claim-ref': {'@idref': 'CLM-00002', 'claim 2'}, 'a wound care composition of ; and'}a wound dressing material.10. The wound dressing of claim 9 , wherein the wound dressing material is a bandage claim 9 , a wipe ...

ANTIMICROBIAL SUPERABSORBENT COMPOSITIONS

A composition has an enzyme that is able to convert a substrate to release hydrogen peroxide; a substrate for the enzyme; and a superabsorbent component, such as a superabsorbent polymer. The composition is in the form of a powder and may form a gel on contact with water.

TISSUE SEALANT IN WHICH COLLAGEN AND FIBRIN ARE MIXED, AND METHOD FOR PREPARING SAME

The present invention relates to a tissue sealant in which collagen and fibrin are mixed and to a method for preparing same. To this end, the method of the present invention comprises the steps of: mixing a first material using fibrinogen and aprotinin; mixing a second material using thrombin, calcium chloride, and collagen; and preparing a third material by mixing the first material and the second material. The tissue sealant prepared by the method may supplement weaknesses, i.e. strength and degradability, of the fibrin sealant which is currently available in the commercial marketplace. Further, the tissue sealant of the present invention is cytophilic and activates blood platelets contained in blood so as to induce tissue regeneration. Thus, quality and reliability of products can be significantly improved so as to satisfy various needs of consumers who are users, thereby presenting good image. 1. A method for preparing a tissue sealant in which collagen and fibrin are mixed , the method comprising:mixing fibrinogen and aprotinin to prepare a first material;mixing thrombin, calcium chloride, and collagen to prepare a second material; andmixing the first material and the second material with each other to prepare a third material.2. The method of claim 1 , wherein the fibrinogen has a concentration of 65-130 mg/mL claim 1 , the aprotinin has a concentration of 1 claim 1 ,000-3 claim 1 ,000 KIU/mL claim 1 , the thrombin has a concentration of 40-600 U/ml claim 1 , the calcium chloride has a concentration of 4-140 mmol/mL claim 1 , and the collagen has a concentration of no more than 60 mg/mL.3. The method of claim 2 , wherein the concentration of the collagen is 10-30 mg/mL.4. A method for preparing a tissue sealant in which collagen and fibrin are mixed claim 2 , the method comprising:preparing a first material including fibrinogen and aprotinin;preparing a second material including thrombin, calcium chloride, and collagen; andputting the first material in one ...

Biocomposites Having Viable Stem Cells and Platelets and Methods for Making and Using the Same

Aspects of the present disclosure include methods for preparing biocomposites having viable stem cells and platelets. Methods according to certain embodiments include combining a composition that contains viable stem cells with a composition the contains platelets in a centrifugation vessel, subjecting the centrifugation vessel to a force of centrifugation to produce two or more fractions such that each fraction includes a component having different density and collecting a fraction from the centrifuge vessel that includes the platelets and viable stem cells. Liquid biocomposites having viable stem cells and platelets and methods for administering the biocomposites to a body site of a subject are also provided.

Nanoparticles for the therapeutic treatment of radiation-induced skin ulcers

A method of treating radiation-induced skin toxicity or skin ulcers with nanoparticles after exposure to ionizing radiation and after an onset of radiation-induced skin toxicity or a radiation-induced skin ulcer by administering intravenously a suspension including fibrinogen-coated albumin nanospheres to a patient. A concentration of the suspension being sufficient to at least one of promote healing of the skin toxicity or reduce a size of the skin ulcer. The suspension can include fibrinogen-coated albumin nanospheres, sorbitol and/or caprylate. The suspension can be utilized for treating a patient to reduce an amount of blood loss in an organ of the patient or for treating a patient to mobilize stem cells or progenitor cells to accelerate healing of a wound.

Cell Preparations For Extemporaneous Use, Useful For Healing And Rejuvenation In Vivo

The present invention relates to new plasma or new platelet-rich plasma preparations, new cell dissociation methods, new cell associations or compositions, a method of preparation thereof, a use thereof, devices for the preparation thereof and preparations containing such a platelet-rich plasma preparation and cell associations or compositions. Specifically, the invention provides plasma or platelet-rich plasma alone or in cell composition preparations for use in tissue regeneration and bone regeneration and pain reduction. 1. A system for preparing a cell preparation , comprising:a first container having a cap and containing an anticoagulant, said cap sealing said anticoagulant in said first container, wherein said first container is a tube adapted to centrifuge whole blood for a length of time to separate platelet rich plasma;a second container containing hyaluronic acid; andan applicator device adapted to administer to a patient a cell preparation formed by mixing said platelet rich plasma from said first container and said hyaluronic acid from said second container.2. The system of claim 1 , further comprising a separator gel sealed in said tube claim 1 , said separator gel forming a barrier between said platelet rich plasma and red blood cells when said tube is centrifuged for a length of time.3. The system of claim 1 , wherein said anticoagulant comprises a sodium citrate solution.4. The system of claim 1 , wherein said applicator device comprises a double syringe adapted to mix said platelet rich plasma and said hyaluronic acid to form said cell preparation at a treatment site of said patient.5. The system of claim 1 , wherein said system is adapted to permit mixing of said platelet rich plasma and said hyaluronic acid in said second container.6. The system of claim 1 , wherein said second container and said applicator device comprise the same device.7. The system of claim 1 , further comprising:phlebotomy accessories comprising a needle for drawing blood ...

MULTILAYERED BLOOD PRODUCT

A blood product (), a method for preparing the blood product, a blood product obtainable by the method and a blood product preparing container means. The blood product comprises components from whole blood, especially fibrin, thrombocytes and leukocytes. The blood product () comprises a first layer (), a second layer () and a third layer (). The second layer () is adjacent to the first layer () and the third layer (). The first layer () defines a first outer surface () of the blood product () and the third layer () defining a second outer surface () of the blood product (). The first layer () comprises a majority of fibrin, the second layer () comprises a majority of thrombocytes and the third layer () comprises a majority of leukocytes. 1. A method to treat a wound , the method comprising:applying, to the wound, a self-supporting, three-layered blood product that comprises in consecutive layers: (a) a first layer including fibrin, (b) a second layer including thrombocytes, and (c) a third layer including leukocytes, wherein the blood product is configured for application to the wound so that the third layer is in direct contact with the wound.2. The method of claim 1 , wherein the third layer comprises leukocytes that are a majority by volume of the third layer.3. The method of claim 1 , wherein the three-layered blood product comprises in substantially parallel layers: fibrin in a majority by volume of a first layer claim 1 , thrombocytes in a majority by volume of a second layer and leukocytes in a majority by volume of a third layer.4. The method of claim 1 , wherein the blood product conforms to continuous contours to which the blood product is applied.5. The method of claim 1 , wherein the blood product can withstand applied stress without rupturing.6. The method of claim 1 , further comprising removing claim 1 , after a centrifugation claim 1 , a blood product from a container as a single claim 1 , self-supporting three-layered blood product of (a) fibrin ...

COLLAGEN-FIBRIN COMPOSITION, METHOD AND WOUND ARTICLES

A method is described. The method includes mixing fibrin and collagen to form a mixture including collagen and fibrin; and reducing the salt concentration below the threshold concentration to form a fibrin. A collagen-fibrin composition is also described. The composition includes a collagen and a fibrin; wherein the composition has a salt concentration below the threshold concentration to form a fibrin. 1. A method comprisingmixing fibrin and collagen to form a mixture comprising of collagen and fibrin; andreducing the salt concentration below the threshold concentration to form a fibrin.2. The method of claim 1 , wherein reducing the salt concentration below the threshold concentration to form a fibrin occurs before mixing fibrin and collagen to form a mixture.3. The method of claim 1 , further comprising dissolving collagen or fibrin in acetic acid.4. The method of claim 1 , wherein the fibrin is formed by mixing fibrinogen and fibrin-forming enzyme.5. The method of claim 1 , wherein reducing the salt concentration comprises rinsing the mixture with an aqueous solution.6. The method of claim 1 , wherein reducing the salt concentration comprises dialyzing the mixture.7. The method of claim 1 , further comprising forming the mixture into a sheet claim 1 , foam claim 1 , or a plurality of pieces.8. The method of claim 1 , further comprising dehydrating the mixture after reducing the salt concentration.9. The method of claim 1 , wherein the dehydrating comprises freeze-drying claim 1 , oven drying claim 1 , critical point drying claim 1 , or combination thereof.10. A collagen-fibrin hydrogel composition prepared by the method of .11. A method comprisingmixing collagen, fibrinogen and fibrin-forming enzyme to form a mixture comprising of collagen and fibrin; andreducing the salt concentration below the threshold concentration to form a fibrin.12. A composition claim 1 , comprising:a collagen anda fibrin;wherein the composition has a salt concentration below the ...

Hemostatic products

A hemostatic product that includes a dry fibrinogen mixture, a dry thrombin mixture and a biologically tolerable liquid. The dry fibrinogen mixture includes fibrinogen and at least one fibrinogen stabilizer. The dry thrombin mixture includes thrombin and at least one thrombin stabilizer. The biologically tolerable liquid is mixed with the dry fibrinogen mixture and the dry thrombin mixture to form the hemostatic product.

CELL PREPARATIONS FOR EXTEMPORANEOUS USE, USEFUL FOR HEALING AND REJUVENATION IN VIVO

The present invention relates to new plasma or new platelet-rich plasma preparations, new cell dissociation methods, new cell associations or compositions, a method of preparation thereof, a use thereof, devices for the preparation thereof and preparations containing such a platelet-rich plasma preparation and cell associations or compositions. Specifically, the invention provides plasma or platelet-rich plasma alone or in cell composition preparations for use in tissue regeneration and bone regeneration and pain reduction. 130-. (canceled)31. A sterilized , vacuum-sealed separator tube for preparing a platelet concentrate from whole blood consisting essentially of:An inlet adapted to introduce whole blood;An anticoagulant;A thixotropic gel; andA cap configured to hermetically seal the separator tube,wherein the separator tube is adapted to be centrifuged in a single centrifugation to separate blood components in the whole blood into a platelet concentrate to be administered to a patient, and red blood cells,wherein the separator tube, anticoagulant, and thixotropic gel are sterilized together and hermetically sealed, andwherein the thixotropic gel is adapted to form a barrier between the platelet concentrate and red blood cells as a result of the centrifugation.32. The separator tube according to claim 31 , wherein the separator tube is adapted to be centrifuged at about 3 claim 31 ,800 RPM for about 3 to about 4 minutes to produce a platelet concentrate having a concentration of platelets of at least about 300 billion platelets per liter.33. The separator tube according to claim 31 , wherein the separator tube has a usable vacuum of from about 8 to about 10 mL.34. The separator tube according to claim 31 , wherein the cap is selected from a bromobutylene rubber stopper and a chlorobutylene rubber stopper.35. The separator tube according to claim 34 , wherein the cap further comprises a polyethylene cover.36. The separator tube according to claim 31 , wherein the ...

Use of photosynthetic scaffolds in tissue engineering

The present invention is concerned with a photosynthetic scaffold that delivers oxygen and its uses for tissue engineering and the treatment of ischemia.

Wound-covering material

Procedures for the production of solid dressing to treat injured tissue

Un procedimiento de producción de un apósito sólido para tratar tejido lesionado en un mamífero que comprende:(a) formar una mezcla acuosa líquida de un componente de fibrinógeno y un activador de fibrinógeno a unatemperatura de entre 2ºC y 8ºC para inhibir la activación del componente de fibrinógeno por parte del activador defibrinógeno; (b) reducir la temperatura entre -10ºC y -196ºC de dicha mezcla acuosa para formar una mezcla acuosacongelada; y (c) reducir el contenido de humedad de dicha mezcla acuosa congelada hasta menos del 53% paraproducir un apósito sólido que tenga una capa hemostática homogénea que consista en dicho componente defibrinógeno y dicho activador de fibrinógeno.

Patent JPS56501129A

Flexible fibrin-based wound dressing and process for its manufacture

Es wird eine biologisch abbaubare, flexible Wundauflage auf Fibrinbasis und ein Verfahren zu ihrer Herstellung beschrieben, bei dem man eine Fibrinogenlösung einer einstufigen oder mehrstufigen Dialyse unterwirft, dann durch Einwirkung einer wässrigen Thrombinlösung auf die Fibrinogenlösung ein flexibles Fibrinvlies bildet und dieses anschließend einer Gefriertrocknung unterwirft. A biodegradable, flexible wound dressing based on fibrin and a process for its production are described, in which a fibrinogen solution is subjected to one-stage or multi-stage dialysis, then a flexible fibrin fleece is formed by the action of an aqueous thrombin solution on the fibrinogen solution and this is then subjected to freeze-drying.

Hemostatic sandwich bandage

Solid dressing for treating wounded tissue

本发明公开了用于处理哺乳动物患者(例如人)的受伤组织的固体敷料，其包括实质上由纤维蛋白原组分和纤维蛋白原活化剂组成的止血层，其中所述止血层是由包含纤维蛋白原组分和纤维蛋白原活化剂的单一的水溶液浇铸或形成的。还公开了使用这些敷料处理受伤组织的方法和可用于制备这些敷料的止血层的冻结组合物。

Supplemented and unsupplemented tissue sealants, their manufacture and use

(57)【要約】 この発明はフィブリンシーラントの包帯またはドレッシングを提供する。ここにこのフィブリンシーラントには、例えば１種またはそれ以上の調節化合物、抗体、抗微生物組成物、鎮痛剤、抗凝固剤、抗増殖剤、抗炎症性化合物、サイトカイン、サイトトキシン、薬剤、増殖因子、インターフェロン、ホルモン、脂質、脱ミネラル化骨または骨形態形成蛋白質、軟骨誘導因子、オリゴヌクレオチド、ポリマー、多糖類、ポリペプチド、プロテアーゼ阻害剤、血管収縮剤または血管拡張剤、ビタミン、ミネラル、その他などから選択した組成物の少なくとも一種を補足してもよい。また、非補足または補足フィブリンシーラントの包帯またはドレッシングの製造法および／または使用法も開示する。

MATERIALS IN THE FORM OF INTERPENETRATING POLYMER ARRAYS ASSOCIATING A FIBRIN GEL AND A POLYETHYLENE GLYCOL NETWORK

BIOLOGICAL GLUE AND ITS USE AS MEDICINE

La présente invention se rapporte à une colle biologique à base de fibrinogène, de facteur VII activé et d'une source d'ions calcium. The present invention relates to a biological glue based on fibrinogen, activated factor VII and a source of calcium ions.

Processes for the production of solid dressing for treating wounded tissue

Disclosed are solid dressings for treated wounded tissue in mammalian patients, such as a human, comprising a haemostatic layer consisting essentially of fibrinogen and a fibrinogen activator, wherein the fibrinogen is present in an amount between 3.0 mg/cm2 of the wound facing surface of the dressing and 13.0 mg/cm2 of the wound facing surface of the dressing. Also disclosed are methods for treating wounded tissue.

Sealant formulation and uses thereof

The present invention relates to a sealant formulation comprising a blend containing fibrinogen and an exogenous activator of a member of a mammalian blood clotting cascade.

Tissue sealant and growth factor-containing preparations that promote accelerated wound healing

Solid dressing for treating wounded tissue

Apparatus for production of fibrin ogen or fibrin glue

This invention relates generally to apparatuses and processes for preparing fibrinogen glue from autologous plasma. More particularly, this invention relates to a novel apparatus comprising a plasma membrane separator to extract and separate the autologous plasma from other undesirable compositions in the blood. The autologous plasma is transferred to a membrane separator to provide separation of the fibrinogen from other compositions with a desirable amount of ether or other suitable solvents containing an-OH group in the presence of a mixing means. The fibrinogen so separated is transferred to a fibrinogen collector which is connected to a vacuum pump through a sterile filter to remove the ether or other suitable solvents contained thereof. A freezer is provided to maintain the autologous plasma in the membrane separator and the fibrinogen in the fibrinogen collector at a desirable temperature. Additionally, a constant temperature bisyringe serves to keep the fibrinogen liquid and mixed with thrombin to form a homogeneous clotting to achieve hemostasis and tissue approximation. A second embodiment which provides a method of producing fibrin glue without the need of ether or organic solvents is also disclosed.

Condensed blood plasma derivative

(57)【要約】本公報は電子出願前の出願データであるた め要約のデータは記録されません。

Supplemented tissue sealant

This invention provides supplemented and unsupplemented tissue sealants (TSs), such as fibrin glue, as well as methods of their production and use. In one embodiment, this invention provides TSs that do not inhibit full thickness skin wound healing. This invention also provides growth factor(s)- and/or drug(s)- supplemented TSs and methods of their production and use. The particular drug(s) or growth factor(s) selected is a function of its use. In one embodiment, the TS is supplemented with a growth factor(s) and can be used to promote: wound healing, such as that of skin or bone; endothelialization of vascular protheses; the proliferation and/or differentiation of animal cells; and/or the directed migration of animal cells. Exemplified embodiments include fibrin glue that is supplemented with: fibroblast growth factor-1, -2 or -4; and/or bone morphogenetic proteins; and polytetrafluorethylene vascular grafts pressure perfused with fibrin glue containing HBGF-1. In another embodiment the supplemented TS is used to produce a localized delivery of a growth factor(s) and/or a drug(s). Exemplified embodiments include fibrin glue supplemented with solid 5-fluorouracil or free base tetracycline. In another embodiment, this invention provides TS supplemented or treated with a substance, such as free base tetracycline or ciprofloxacin HCl, wherein the longevity of the fibrin glue is increased.

Teicoplanin containing topical compositions with delayed release of the active agent

Delayed-release pharmaceutical composition which can be administered topically in the form of a dry product or of a suspension thereof in an inert liquid vehicle containing as sparingly water-soluble product the combination of A) teicoplanin with B) at least one other pharmaceutical agent with, as a rule, basic characteristics.

Hemostatic material capable of absorbing fluid and preparation method and application thereof

本发明涉及一种可吸收流体止血材料，包括止血有效成分和流体基质。所述止血有效成分以固体的形态存在与流体基质中，且与流体基质不发生化学反应。本发明提供的止血材料性质稳定，无致敏性、皮内刺激以及遗传毒性，与血液相容性好，能在体内完全降解，使用安全，应用于出血伤口处时，能够在短时间内完成止血，并明显降低伤口出血量，具有广阔的应用前景。

sealant formulation and uses thereof

a presente invenção se refere a uma formulação de selante compreendendo uma blenda contendo fibrinogênio e um ativador exógeno de um membro de uma cascata de coagulação sanguínea de mamífero. The present invention relates to a sealant formulation comprising a fibrinogen-containing blend and an exogenous activator of a member of a mammalian blood coagulation cascade.

Flexible wound dressing based on fibrin and process for preparation of same

Precipitation of growth-factor-enriched fibrinogen concentrate from platelet rich plasma

Increased fibrinogen yields are obtained by adding a precipitating agent to plasma having a high platelet concentration, such as platelet rich plasma. The precipitating agent may be any of several known agents, including polyethylene glycol and ammonium sulfate. The platelet rich plasma is obtained in the preferred embodiment by subjecting plasma to 'soft spin' centrifugation of about 580G. An automatic, multiple decanting and multiple-speed centrifuge is preferably used to separate anti-coagulated whole blood into the platelet rich plasma component and red blood cells. The proteins, preferably fibrinogen, FXIII, and FVIII, in the platelet rich component are precipitated, and the proteins and platelets are then concentrated by further centrifugation.

FIBRINOGEN CONCENTRATE OBTAINED FROM BLOOD PLASMA, PROCEDURE AND INSTALLATION FOR PREPARATION.

LA PRESENTE INVENCION SE REFIERE A UN CONCENTRADO DE FIBRINOGENO CARACTERIZADO PORQUE ESTA DESPROVISTO DE CONTAMINANTES VIRALES Y PORQUE SU PUREZA ES SUPERIOR A 95%. LA PRESENTE INVENCION SE REFIERE TAMBIEN AL PROCEDIMIENTO DE OBTENCION DE DICHO CONCENTRADO DE FIBRINOGENO. THE PRESENT INVENTION REFERS TO A CHARACTERIZED FIBRINOGEN CONCENTRATE BECAUSE IT IS DESPROVED OF VIRAL POLLUTANTS AND BECAUSE ITS PURITY IS OVER 95%. THIS INVENTION REFERS TO THE PROCEDURE FOR OBTAINING THE FIBRINOGEN CONCENTRATE.

Enriched plasma derivative for promoting wound sealing and wound healing

A sprayable preparation for accelerated hemostasis and optimized biochemical control of wound closure contains a powdery mixture of 15 to 60% by weight of thrombin, 5 to 80% by weight of a desiccating and stabilizing agent, viz., albumin, globulin and/or fibrinogen, and 1 to 10% by weight of a fibrinolysis inhibitor. The powdery mixture is suspended in a low-boiling, anhydrous solvent, which is used as a propellant. For effective wound closure and coverage, a spray jet of this suspension is directed onto the wound under evaporation of the solvent so that substantially only the dry, solid powdery mixture reaches the wound. This method of application by spraying is also disclosed.

Cell preparations for extemporaneous use, useful for in vivo healing and rejuvenation

Un tubo separador de vidrio para la preparación de una composición de concentrado de plaquetas, en donde el contenido del tubo consiste en un gel tixotrópico a base de poliéster y una solución tamponada de citrato de sodio a 0,10 M. A glass separator tube for the preparation of a platelet concentrate composition, where the content of the tube consists of a thixotropic polyester-based gel and a 0.10 M sodium citrate buffered solution.

Tissue sealant in which collagen and fibrin are mixed, and method for preparing same

The present invention relates to a tissue sealant in which collagen and fibrin are mixed and to a method for preparing same. To this end, the method of the present invention comprises the steps of: mixing a first material using fibrinogen and aprotinin; mixing a second material using thrombin, calcium chloride, and collagen; and preparing a third material by mixing the first material and the second material. The tissue sealant prepared by the method may supplement weaknesses, i.e. strength and degradability, of the fibrin sealant which is currently available in the commercial marketplace. Further, the tissue sealant of the present invention is cytophilic and activates blood platelets contained in blood so as to induce tissue regeneration. Thus, quality and reliability of products can be significantly improved so as to satisfy various needs of consumers who are users, thereby presenting good image.

Materials in the form of interpenetrating polymer networks that combine a fibrin gel and a polyethylene glycol network

Procedimiento de preparación de un material en forma de red polimérica interpenetrante (RPI) que combina un gel físico de fibrina y una red de polietilenglicol (PEG), que comprende las siguientes etapas: i) preparar una mezcla introducido en un tampón - una solución de fibrinógeno, - monómeros de fórmula (I): X1-(CH2-CH2-O)n-X2 en la que X1 y X2, son grupos químicos idénticos o diferentes, seleccionados entre el grupo que comprende vinilo, acrilato, metacrilato o alilo y n es un número entre 1 y 140, - opcionalmente monómeros de fórmula (II) seleccionados entre los derivados de polietilenglicol que tienen un grupo seleccionado entre el grupo que comprende -CH3, -NH2, -OH, -CH2CH3, le vinilo, acrilato, metacrilato o alilo; derivados de acrilato, metacrilato y estireno seleccionados entre el grupo que comprende hidroxietilmetacrilato, hidroxietilacrilato, acetato de vinilo, N-vinil pirrolidona, N-vinil piridina, acrilonitrilo, ácido acrílico, estireno sulfonato sódico, bromuro de (vinilbencil)trimetil-amonio, cloruro de (vinilbencil)trimetil-amonio, cloruro de trimetilviniloxicarbonilmetil- amonio, bromuro de trimetil-viniloxicarbonilmetil-amonio, bromuro de trietil-2- viniloxicarbonil-etil)-amonio, bromuro de aliloxicarbonilmetil-trimetil amonio, poli(etilenglicol)metacrilato, poli(etilenglicol)acrilato, - un iniciador de la polimerización; ii) preparar una mezcla de reacción añadiendo una solución de trombina a la mezcla preparada en i); iii) incubar la mezcla de reacción obtenida en ii) a una temperatura entre 20 ºC y 40 ºC; iv) realizar una polimerización y reticulación de los monómeros de fórmula (I) opcionalmente con los monómeros de fórmula (II). Process for preparing a material in the form of an interpenetrating polymeric network (IPN) that combines a physical fibrin gel and a polyethylene glycol (PEG) network, comprising the following steps: i) preparing a mixture introduced in a buffer - a solution of fibrinogen, - monomers of formula (I): X1-(CH2-CH2-O)n-X2 ...

Solid dressing for treating wounded tissue

Formed sheet product and hemostatic material

A formed sheet product of a polymer composition comprising at least one protein selected from the group consisting of fibrinogen and thrombin and at least one polymer selected from the group consisting of an aliphatic polyester and a water-soluble polymer, and a laminated formed sheet product comprising a first polymer composition layer composed of fibrinogen and a water-soluble polymer and a second polymer composition layer composed of thrombin and an aliphatic polyester are provided. These formed products are applied onto a wound site and function as a hemostatic material.

ENRICHED PLASMA DERIVES TO SUPPORT WOUND CLOSURE AND HEALING.

A preparation for accelerated hemostasis and optimized biochemical control of wound closure ("tissue adhesive") consists only of solid, powdery, biologically active constituents and contains 60 to 96% by weight of fibrinogen, which is largely liberated from cryo-insoluble globulin, 0.05 to 5% by weight of a fibrinolysis inhibitor, and 0.1 to 15% by weight of thrombin and/or prothrombin. For use, this enriched plasma derivative may be applied in the form of a dry, powdery mixture immediately and directly onto the wound or in the area of operation, respectively. Further application methods provide atomizing, spraying, or foaming of the powdery mixture by means of a propellant.

Hemostatic compositions containing sterile thrombin

The present invention includes sterilized hemostatic compositions that contain a continuous, biocompatible liquid phase having a solid phase of particles of a biocompatible polymer suitable for use in hemostasis and that is substantially insoluble in the liquid phase, and sterile thrombin, each of which is substantially homogenously dispersed throughout the continuous liquid phase, and methods for making such compositions.

Enriched plasma derivative for promoting wound sealing and wound healing

A sprayable preparation for accelerated hemostasis and optimized biochemical control of wound closure contains a powdery mixture of 15 to 60% by weight of thrombin, 5 to 80% by weight of a desiccating and stabilizing agent, viz., albumin, globulin and/or fibrinogen, and 1 to 10% by weight of a fibrinolysis inhibitor. The powdery mixture is suspended in a low-boiling, anhydrous solvent, which is used as a propellant. For effective wound closure and coverage, a spray jet of this suspension is directed onto the wound under evaporation of the solvent so that substantially only the dry, solid powdery mixture reaches the wound. This method of application by spraying is also disclosed.

"biological glue and its use as a medicine"

a presente invenção refere-se a uma cola biológica contendo fibrinogênio e fator vii ativado. The present invention relates to a biological glue containing fibrinogen and activated factor vii.

Multilayered blood product

A blood product (10), a method for preparing the blood product, a blood product obtainable by the method and an apparatus for performing the method. The blood product comprises components from whole blood, especially fibrin, thrombocytes and leukocytes. The blood product (10) comprises a first layer (21), a second layer (22) and a third layer (23). The second layer (22) is adjacent to the first layer (21) and the third layer (23). The first layer (21) defines a first outer surface (24) of the blood product (10) and the third layer (23) defining a second outer surface (25) of the blood product (10). The first layer (21) comprises a majority of fibrin, the second layer (22) comprises a majority of thrombocytes and the third layer (23) comprises a majority of leukocytes.

wound dressing

A presente invenção provê kits absorventes para tratamento de ferimento que compreendem um conjunto de composições hemostáticas incluindo pelo menos (1) uma primeira composição hemostática incluindo um primeiro polissacarídeo reticulado selecionado do grupo consistindo em ciclo dextrina e dextrano, e (2) uma segunda composição hemostática incluindo um segundo polissacarídeo reticulado selecionado do grupo consistindo em ciclo dextrina e dextrano. Em algumas modalidades, a primeira composição hemostática tem um primeiro grau de reticulação, e a segunda composição hemostática tem um segundo grau de reticulação maior que o primeiro grau de reticulação. São também providos métodos de tratamento de um ferimento através de seleção de uma composição hemostática a partir do conjunto mostrado de composições hemostáticas, e administração de composição hemostática selecionada a um sítio do ferimento. The present invention provides absorbent wound treatment kits comprising a set of hemostatic compositions including at least (1) a first hemostatic composition including a first cross-linked polysaccharide selected from the group consisting of dextrin and dextran cycle, and (2) a second hemostatic composition including a second cross-linked polysaccharide selected from the group consisting of dextrin and dextran cycle. In some embodiments, the first hemostatic composition has a first degree of crosslinking, and the second hemostatic composition has a second degree of crosslinking greater than the first degree of crosslinking. Wound treatment methods are also provided by selecting a hemostatic composition from the shown set of hemostatic compositions, and administering selected hemostatic composition to a wound site.

Platelet lysate compositions and uses thereof

本发明涉及用于向生物靶标提供机械支持和/或药剂的组合物、试剂盒和方法。具体地，所述组合物包括血小板裂解物、纤维蛋白原和凝血酶。所述组合物可以用于治疗伤口/损伤(例如，角膜)并且用于包含组织培养物的其它应用。

sealant formulation and uses thereof

a presente invenção se refere a uma formulação de selante compreendendo uma blenda contendo fibrinogênio e um ativador exógeno de um membro de uma cascata de coagulação sanguínea de mamífero.

Ionic liquids that sterilize and prevent biofilm formation in skin wound healing devices

Compositions for enhancing wound healing are disclosed herein. Also disclosed are methods of making the compositions and methods of using the compositions for the prevention of biofilm formation and for the inhibition of pathogen growth and proliferation.

Composite material

The present invention provides a composite material comprising lactoferrin and a bioactive glass. The invention also relates to pharmaceutical compositions containing the composite material. Further aspects of the invention relate to the use of the composite material of the for treating a wound, treating or preventing bacterial or viral infections in a wound, preventing viral transmission, regenerating bone, treating osteoporosis, preventing or alleviating bleeding in a wound, sterilising a wound and/or controlling haemorrhaging.

Sheet preparation for tissue adhesion

시트형 지지체의 한쪽 면에 피브리노겐 성분이 고정되고, 피브리노겐 성분이 고정되어 있지 않은 다른 쪽 면에 트롬빈 성분이 고정되고, 또한 양 성분이 서로 분리해서 고정화되어 있는 것을 특징으로 하는 시트 제제, 및 그 제조방법.

Tissue sealant in which collagen and fibrin are mixed, and method for preparing same

Tissue sealant and growth factor containing compositions that promote accelerated wound healing

This invention provides a growth factor-supplemented tissue sealant and methods for using said sealant to promote wound healing, endothelialization of vascular protheses, and the in vitro proliferation and differentiation of animal cells. In particular, this invention provides fibrin glue that is supplemented with at least one growth factor, such as a heparin binding growth factor and/or bone morphogenic proteins. The particular growth factor or factors selected is a function of its use.

Depot formulations

Une formulation à effet retard, comprenant de la fibronectine ou un fragment de celle-ci, un agent de fixation de facteur de croissance lié à la fibronectine et un facteur de croissance lié à l'agent de fixation, est utilisée pour favoriser la cicatrisation en combinaison avec des protéines d'adhésion cellulaire à orientation macroscopique. Les formulations à effet retard permettent d'influer sur le processus de cicatrisation de façon que des résultats améliorés et plus satisfaisants d'un point de vue esthétique soient obtenus. A delayed-release formulation comprising fibronectin or a fragment thereof, a fibronectin-bound growth factor binding agent and a binding agent-related growth factor is used to promote wound healing. combination with macroscopically oriented cell adhesion proteins. Delayed formulations influence the healing process so that improved and more aesthetically pleasing results are achieved.

Sheet preparation for tissue adhesion

一种片制剂及其制备方法，所述片制剂的特征在于，血纤蛋白原固定在片形载体的一个表面上，凝血酶固定在片形载体未固定血纤蛋白原的另一个表面上，并且血纤蛋白原和凝血酶相互分开地固定。

fibrous product formed in lamina, product formed in laminated lamina, hemostatic material, adhesive material in organic fabric or closure material in organic fabric

produto fibroso formado em lâmina, produto formado em lâmina laminado, material hemostático, material adesivo em tecido orgânico ou material de fechamento de tecido orgânico são providos os seguintes: uma moldagem de lâmina de uma composição de polímero que contém pelo menos um tipo de substância de proteína selecionada a partir do grupo que consiste de fibrinogênios e trombinas e pelo menos um tipo de polímero selecionado a partir do grupo que consiste de poliésteres alifáticos e polímeros solúveis em água; e uma moldagem de lâmina laminada contendo uma primeira camada de composição de polímero contendo um fibrinogênio e um polímero solúvel em água e uma segunda camada de composição de polímero contendo a trombina e um poliéster alifático. estas moldagens de lâmina são aplicadas aos locais machucados e funcionam como materiais hemostáticos.

Hemostatic compositions containing sterile thrombin

The present invention includes sterilized hemostatic compositions that contain a continuous, biocompatible liquid phase having a solid phase of particles of a biocompatible polymer suitable for use in hemostasis and that is substantially insoluble in the liquid phase, and sterile thrombin, each of which is substantially homogenously dispersed throughout the continuous liquid phase, and methods for making such compositions.

Methods of making concentrated fibrinogen containing compositions and associated systems for preparing fibrin glue

The present invention is drawn to concentrated fibrinogen compositions and associate methods and use thereof. The concentrated fibrinogen compositions can be produced by adding a sufficient amount of a cationic agent, such as protamine, to a fibrinogen containing fluid to cause the fibrinogen to form a fibrinogen precipitate; collecting the fibrinogen precipitate by a collection means, such as centrifugation; and suspending or solubilizing the fibrinogen precipitate in a liquid vehicle to form a concentrated fibrinogen composition. The concentrated fibrinogen compositions can be incorporated into systems for making fibrin glues and be used in treating wounds.